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ABSTRACT 
Interaction of the Human Serine Protease Inhibitor Alpha-1-antitrypsin 
with Cryptosporidium parvum 
by 
John Russell Forney, Doctor of Philosophy 
Utah State University, 1997 
Major Professor: Dr. Mark C. Healey, DVM, PhD 
Department: Biology 
The human serine protease inhibitor (serpin) alpha-1-antitrypsin 
(AAT) was studied for potential interaction with components of the 
protozoan parasite Cryptosporidium parvum. A homogenate prepared from 
iii 
C. parvum oocysts was incubated with purified human AAT, and complexes 
formed between the serpin and components of the homogenate were detected 
using an enzyme-linked immunosorbent assay (ELISA). Serpin:parasite 
interactions were effectively blocked by preincubating AAT with a cognate 
target enzyme, porcine pancreatic elastase, prior to performing the ELISA on 
the homogenate. Incubation of a mixture of C. parvum oocysts and 
sporozoites with AAT demonstrated preferential fluorescence labeling of the 
sporozoite surface membrane by indirect immunofluorescence assay. 
Localization of serpin complexes on sporozoites was confirmed by 
immunogold electron microscopy. 
iv 
AAT was evaluated for in vitro anticryptosporidial activity in a bovine 
fallopian tube epithelial (BFTE) cell culture system using both oocysts and 
filter-purified sporozoites as inocula. Serial dilutions of AAT were mixed 
with oocysts (or sporozoites) and used to inoculate BFTE cell monolayers. 
Inoculated cells were maintained at 37°C/ 5% C02 and collected at 24-, 48-, 72-, 
and 96-hr post-inoculation intervals. The addition of AAT and other select 
protease inhibitors (i.e., antipain, aprotinin, leupeptin, soybean trypsin 
inhibitor, and phenylmethylsulfonyl fluoride) significantly inhibited parasite 
infection (P<O.Ol) in a concentration- and time-dependent manner when 
bleach-decontaminated oocysts were used in the inoculum. 
The anticryptosporidial activity of AAT is postulated to be linked to an 
antagonistic effect on oocyst excystation and, putatively, the forced 
expenditure of bioenergetic reserves prior to host cell invasion. This 
postulate was supported by the observations that serpin activity had no 
statistically significant effect on reducing established in vitro infections (i.e., 
24 hr post-inoculation prior to addition of AAT) and did not inhibit infection 
of BFTE cells when inoculated with sporozoite preparations. The combined 
application of AAT and the aminoglycoside paromomycin demonstrated a 
synergistic anticryptosporidial effect on in vitro infection and suggested the 
basis for a multi-agent therapeutic protocol in preventing cryptosporidiosis. 
These studies collectively demonstrated an anticryptosporidial potential for 
serine protease inhibitors, in particular for AAT, and suggest an alternative 
approach to conventional therapeutic strategies. (175 pages) 
v 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
INTRODUCTION 
In a span of less than 20 years, Cryptosporidium parvum has emerged 
from the initial reports of human infection in 1976 to world-wide recognition 
as an infectious agent of considerable morbidity in the AIDS patient 
population. This enteropathogenic parasite invades the intestinal epithelium 
and is capable of sustaining chronic patent infection in susceptible hosts, a 
condition exacerbated by the present lack of efficacious therapy. Research 
emphasizing a more thorough understanding of the parasite's developmental 
maturation and efforts to identify strategies for chemotherapeutic 
intervention are both timely and relevant. 
This dissertation presents a succession of investigative studies that 
have enhanced the collective knowledge of the cellular physiology and 
immunobiology of C. parvum. The narrative is organized in a multiple-
paper format supporting a common thematic focus; the functional interaction 
between a human serine protease inhibitor (serpin), alpha-1-antitrypsin 
(AA T), and the early developmental stages of the parasite. In addition to this 
introduction, the first chapter reviews the literature and summarizes the 
research objectives inherent to the studies presented in subsequent chapters. 
The literature review is topically arranged and chronicles the relevant 
findings of other investigators that influenced the current undertaking. 
2 
Chapter 2 describes the initial study identifying an interaction between 
AAT and C. parvum and provides an impetus for the evaluation of the in 
vitro anticryptosporidial activity of AAT (Forney et al., 1996b). The discussion 
section presents a hypothesized role for AAT in reducing the vulnerability of 
host cells to parasite protease activity during the early stages of infection. The 
implications of this study suggest several previously unexplored 
characteristics of the immunobiology of C. parvum and potentiate an innate 
defense mechanism against cryptosporidial infection in humans that is 
mediated, at least in part, by intrinsic serpin activity. 
Chapter 3 characterizes the functional significance of the interaction 
between protease inhibitors and C. parvum. This chapter is based on the first 
published report demonstrating a definitive association between proteolytic 
activity and oocyst excystation and provides evidence of an antagonistic effect 
by serine protease inhibitors on excystation (Forney et al., 1996c). Further, it 
was demonstrated that C. parum expressed multiple proteolytic enzyme 
activities during excystation; 1 protease component was inhibited by select 
serine protease inhibitors and the other component was susceptible to 
inhibition by the cysteine protease inhibitor L-trans-epoxysuccinyl-
leucylamindo-( 4-guanidino )-butane (E-64). 
Chapter 4 provides a thorough and systematic evaluation of the 
antagonistic effect of AAT on oocyst excystation (Forney et al., 1997). 
Experiments were performed to discern the influence of oocyst wall 
permeability and the effect of inoculation source (i .e., oocysts or sporozoite) 
3 
on AAT activity. Further, in vitro efficacy was monitored over extended 
post-inoculation incubation periods and against established infections to 
evaluate serpin activity against asexual intermediates of C. parvum. An 
experimental protocol involved the reapplication of AAT at 24-hr intervals to 
determine whether bioavailability had a significant impact on in vitro 
activity. This final manipulation had no effect on in vitro efficacy, suggesting 
that the biological availability of the serpin in cell culture was not a limiting 
factor in its anticryptosporidial activity. 
Chapter 5 incorporates a series of concise manuscripts (i.e., research 
notes, short communications) derived from studies investigating the 
anticryptosporidial potential of protease inhibitors in a bovine fallopian tube 
epithelial (BFTE) cell culture system. The first section reports the use of 
selected serine protease inhibitors to reduce C. parvum infectivity in BFTE 
cells (Forney eta!., 1996a). The following section summarizes the results of 
the initial in vitro study evaluating the anticryptosporidial activity of AAT 
(Forney eta!., 1996d). The final section of Chapter 5 describes the synergistic 
activity of AAT in combination with the aminoglycoside paromomycin. This 
final note presents a strategy for chemotherapeutic intervention that includes 
compounds targeting different developmental attributes of the parasite, such 
as oocyst excystation and propagation of asexual intermediates. 
Concluding remarks in Chapter 6 summarily review the relative 
contributions of each of the individual studies and unify the collective results 
in a final discussion of C. parvum excystation and infectivity. Speculation is 
4 
made regarding the potential therapeutic application of protease inhibiting 
compounds in treating chronic cryptosporidiosis, in both single and multiple 




E. E. Tyzzer (1907) is acknowledged with the first published report of a 
cryptosporidial organism when he described a sporozoan found in the peptic 
glands of laboratory mice. He further detailed the characteristic morphology 
and life-cycle stages of this parasite and established the basis for the species 
description of Cryptosporidium muris (Tyzzer, 1910). Two years later Tyzzer 
(1912) described a second species, C. parvum, in the small intestine of 
laboratory mice. The next 50 years witnessed very little in the way of scientific 
enlightenment regarding C. parvum; the parasite was generally considered to 
be a commensal organism in the intestinal tract of vertebrate hosts. Various 
reports of additional Cryptosporidium species were recorded during this 
period, primarily based on an assumption of unique host specificity. The 
majority of these reports have since been repudiated by cross-transmission 
studies that define C. parvum as a multi-host parasite exhibiting little, if any, 
host specificity (Current, 1986; Levine, 1986; Upton et al., 1989; Current and 
Garcia, 1991; O'Donoghue, 1995). 
Levine (1986) systematically reviewed and updated the salient 
characteristics of the genus Cryptosporidium and validated its taxonomic 
classification in the phylum Apicomplexa, class Sporozoasida, order 
Eucoccidiorida. Cryptosporidium spp. are further classified into the suborder 
Eimeriorina based on their sexual reproductive stages (gamonts) and 
nonmotile zygote (oocyst). The genus is the sole representative of the family 
Cryptosporidiidae, distinguished by the presence of "free" sporozoites (i.e., 
lacking an intervening sporocyst) within the oocyst and the presence of an 
attachment organelle ("feeder") at the base of the parasitophorous vacuole 
(Johnson eta!., 1990; Cai et al., 1992). 
In many respects, Cryptosporidium exhibits a similar pattern of 
ontogeny to that observed in other coccidian genera, such as Eimeria and 
Isospora, with a monoxenous (single host) life cycle (Fayer et a!., 1990; 
O'Donoghue, 1995). However, it is the differences in propagation and host 
cell infection that characterize this enigmatic parasite. The infective stage is 
the oocyst, a small spherical to elliptical shaped form approximately 4-7 mm 
in diameter, each one containing 4 sporozoites. Sporozoites excyst in the 
lumen of the small intestine and invade the apical surface of epithelial cells 
lining the microvilli. Within an intracellular, but extracytoplasmic, 
parasitophorous vacuole, the sporozoite differentiates into a trophozoite and 
undergoes multiple asexual reproduction (merogony) producing meronts 
(Gobel and Brandler, 1982; Current, 1986; Rosales et al., 1992, 1993). 
5 
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The formation of an intramembranous vacuole by C. parvum appears 
to be a unique evolutionary characteristic of this parasite. A thorough search 
of the literature failed to reveal any phylogenetically related organism that 
forms a similar developmental residence within an infected host cell. There 
are many examples of microbial pathogens that occupy a more conventional 
intracellular niche, within an intracytoplasmic vacuole. Such is the case for 
obligate intracellular bacteria represented by the genera Shigella, Listeria, 
Neisseria, and Vibrio as well as for the protozoan parasites Plasmodium and 
Toxoplasma spp . The biochemical and molecular mechanism that fosters the 
formation of the cryptosporidial parasitophorus vacuole is a confounding 
puzzle to the parasitology community. 
Two distinct types of meronts exist in the cryptosporidial life-cycle 
(Vetterling et a!., 1971; Current, 1986; Fayer eta!., 1990; Ostrovska and Papema, 
1990). The mature type I meront develops 8 merozoites that are released from 
their intramembranous location and recycle the infection in the intestinal 
epithelium. Type II meronts contain 4 merozoites that, upon release, infect 
other intestinal epithelial cells and initiate a sexual reproductive cycle 
(syngamy). Merogony amplifies parasite numbers and the type I meront can 
putatively undergo multiple propagatory cycles before differentiating into the 
type II meront stage. Separate macrogamonts and microgamonts develop 
from type II merozoites, and microgametes are released to fertilize mature 
macrogamonts (Gobel and Brandler, 1982). The resulting zygote undergoes 
sporogony within the host epithelial cell and, upon maturation, is released 
into the intestinal lumen as a infective oocyst (Bird and Smith, 1980; 
Yoshikawa and Iseki, 1992). Approximately 80% of the sporulated oocysts are 
contained within a thick, multi-layered, environmentally resistant wall and 
pass from the host in fecal excrement. The remaining oocysts are 
characterized by a single, thin oocyst wall and are thought to excyst during 
lumenal passage. Thin-walled oocysts perpetuate an autoinfective cycle in 
the chronically infected host (Current, 1985; Current and Reese, 1986; Fayer et 
a!. , 1990). In light of the multiple cycling of type I meronts and the 
autoinfective potential of thin-walled oocysts, it is not difficult to visualize 
the sustained 'proliferation of C. parvum that accompanies patent infection. 
The role of surface adhesin molecules in the recognition and 
attachment of C. parvum to the membrane of susceptible epithelial cells is 
not clearly defined. Similarly, the sequence of biochemical and physiological 
events that result in hypertrophy of microvilli at the site of parasite 
attachment, fusion of extended microvillar membranes, and retention of the 
parasitophorous vacuole within the host cell membrane is poorly 
understood. Investigators have reported a putative role for surface-expressed 
glycoproteins or lectin-associated membrane affinity to aid in the initial 
attachment of C. parvum sporozoites to host cells (Bonnin et a!., 1991a, 1991b; 
Tilley eta!., 1991; Petersen eta!., 1992; Thea eta!., 1992; Hamer eta!., 1994; Joe 
eta!., 1994; Mitschler eta!., 1994; Tilley and Upton, 1994). The role of specific 
receptor-ligand interactions between invasive C. parvum stages (i.e., 
sporozoites, type I and II merozoites, microgametes) and the host cell has not 
7 
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been thoroughly investigated. It is conceivable that cryptosporidial protease-
like components are involved in interactions at the host cell membrane level 
such as has been demonstrated with related coccidians (Adams and Bushell, 
1988; Fuller and McDougald, 1990). Bristow eta!. (1995) reported a cell surface 
adhesion and fusion mechanism between the human immunodeficiency 
virus and host cells that involved recognition between serine protease-like 
receptors and corresponding structures analogous to serpin reactive sites. The 
initial adherence of sporozoites to host cell membranes may facilitate the 
spatial orientation of parasite proteases that further enhance cell attachment 
and, potentially, contribute to the parasite's unique intramembranous 
location within infected cells. 
Panciera eta!. (1971) reported the initial incidence of disease associated 
with C. parvum when he cited the parasite as the causative agent of diarrhea 
in calves. Twenty-five years later, the literature abounds with reports of 
diarrheal illness in many different animals attributed to C. parvum. 
Veterinary medicine recognizes this protozoan as a significant etiology of 
neonatal diarrhea in calves and lambs, with a concomitant economic impact 
on the domestic animal industry. A multitude of reports, citing 
cryptosporidiosis in 170 different animal species and a well documented 
record of pathogenesis in over 50 countries worldwide, clearly expands 
Tyzzer's initial description of a benign commensal to a ubiquitous enteric 
pathogen (Fayer eta!., 1990; Current and Garcia, 1991; Powell, 1994). 
Human cryptosporidiosis 
Despite the association between C. parvum and disease in animals for 
over two decades, it was the initial reports of human cryptosporidiosis that 
kindled the greatest spark of international scientific interest in the parasite. 
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In 1976, Cryptosporidium spp. was independently reported in two 
immunocompromised patients as the primary etiology of profuse diarrhea 
(Meisel et al., 1976; Nime et al., 1976). Reports of clinical illness from 
cryptosporidiosis in both immunocompetent and immunocompromised 
patient populations appeared intermittently in the medical literature over the 
next decade. Ungar et al. (1990a) and Petersen (1992) have reviewed the 
increased incidence of human cryptosporidiosis in the immunocompromised 
host, a trend that parallels the rise in HIV infection noted in the mid-1980s 
and persists in the current medical and scientific literature (Brandonisio et al., 
1993; Cotte et al., 1993; Georgiev, 1993; Goodgame et al., 1993, 1995; Moroni et 
al., 1993; Giang et al., 1994; Mifsud et al., 1994; Molbak et al., 1994; Sorvillo et 
al., 1994). The conclusive association between C. parvum infection and a 
chronic, watery diarrheal illness in patients with AIDS has substantiated 
interest in the immunology and biology of this protozoan (Current et al., 
1983; Tzipori, 1983; Casemore, 1990; Ungar et al., 1991; Gellin and Soave, 1992). 
The epithelial lining of the microvilli in the small intestine is the 
preferential site of parasite infection, and incubation periods ranging from 2-
24 days are typically noted in human hosts (Tzipori et al., 1981a, 1981b; 
Goodgame et al., 1995). The ensuing diarrhea is generally self-limited in an 
10 
otherwise healthy individual with a spectrum ranging from asymptomatic, 
subclinical cases to acute diarrhea, abdominal cramps and nausea of 1-3 wk 
duration (Phillips eta!., 1992). Spontaneous eradication of the parasite from 
the intestinal mucosa and protective acquired immunity is the general 
outcome of infection in the immunocompetent individual. The most severe 
consequence of human cryptosporidiosis occurs in the immunodeficient host. 
These individuals frequently develop a profuse, protracted diarrheal illness 
which progresses to a chronic patent infection exhibiting colonization of the 
intestinal epithelium and, potentially, dissemination into the alveolar and 
tracheal epithelium, stomach, pancreatic duct, and gall bladder (Garone et a!., 
1986; Ramsden and Freeth, 1989; Travis eta!., 1990; Petersen, 1992; Giang eta!., 
1994; Mifsud et a!. , 1994). Fluid loss from voluminous diarrhea can become 
life-threatening for the chronically infected patient. This emerging clinical 
scenario has established C. parvum as a significant opportunistic pathogen 
and a cause of severe morbidity in susceptible patients (Davis et a!., 1987; 
Kahn eta!., 1987; Petersen, 1992; Sun, 1994). Investigators have further 
reported an association between severe cryptosporidiosis and profound 
malnutrition that, if unresolved, results in a clinically apparent illness in 
children closely resembling that seen in AIDS patients (MacFarlane and 
Horner-Bryce, 1987; Sallon et a!., 1988; Kuhls et a!., 1992; Guarino et a!., 1993). 
The underlying pathophysiology of cryptosporidial diarrhea is 
unknown. Histologically, C. parvum infection is characterized by blunted, 
fused microvilli in the small intestine with a concomitant crypt hyperplasia 
11 
(Tzipori, 1983; McDonald and Bancroft, 1994; Goodgame et al., 1995; Moore et 
a!., 1995). The voluminous, secretory nature of the resulting diarrhea, 
frequently termed "cholera-like," suggests an enterotoxogenic etiology, but 
studies have yet to define an operative agent (Brown et al., 1992; Chui and 
Owen, 1994; Eggleston et al., 1994; Guarino et al., 1994). 
Cryptosporidiosis has emerged dramatically as a significant water-borne 
infection, best illustrated by the massive outbreak of cryptosporidiosis in 
Milwaukee, Wisconsin in 1993 that totaled an estimated 403,000 cases of 
infection (MacKenzie et al., 1994). In Milwaukee and related outbreaks, the 
infective stage of the parasite (i.e., oocyst) has been recovered from treated 
municipal water supplies (Peeters et al., 1989; Korich et al., 1990; Robertson et 
al., 1992; MacKenzie et al., 1994; Aldom and Chagla, 1995). A growing body of 
evidence suggests that cryptosporidial contamination of run-off water from 
commercial livestock operations and human sewage treatment facilities 
perpetuates a significant parasite reservoir in the environment (Jokipii et al., 
1985; Madore eta!., 1987; Current and Garcia, 1991; Hansen and Ongerth, 1991; 
LeChevallier et al., 1991; MacKenzie et al., 1994). In both laboratory and 
environmental settings, C. parvum oocysts demonstrate exceptional 
resistance to chemical treatment and disinfection, particularly at those levels 
of treatment determined to be safe for human consumption (Campbell et al., 
1982, 1993; Fayer et al., 1990; Fayer, 1994, 1995). The Centers for Disease 
Control (1994) now consider cryptosporidiosis a major public health concern 
for the United States and a significant emerging disease threat. 
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The severity and chronicity of human cryptosporidiosis is accentuated 
by the present lack of clinically efficacious therapy and an incomplete 
understanding of the immunobiology of the parasite (Flanigan and Soave, 
1993; Moroni et al., 1993; Flanigan, 1994; O'Donoghue, 1995). Reports of 
efficacious anticryptosporidial agents are largely based on anecdotal evidence 
that has not been sustainable in controlled clinical trials (Wittenberg et al., 
1989; Zu et al., 1992; Flanigan and Soave, 1993). Additionally, in vitro 
evidence of potential therapeutic efficacy against cryptosporidial infection has 
not been successfully transferred to in vivo laboratory models or to infected 
patients in a reproducible fashion (Wittenberg et al., 1989; Zu et al., 1992; 
Flanigan and Soave, 1993; Verdon et al., 1994). Attempts to employ 
conventional chemotherapeutic agents with established antimicrobial, 
antifungal, or antiviral efficacy have not been consistently and reproducibly 
successful in preventing or abrogating C. parvum infection in humans. 
The immune status of the host appears to be the most significant 
determinant of C. parvum infection severity. Predictably, immunotherapy 
and immunological intervention highlight current research efforts to 
develop an effective anticryptosporidial protocol. Intervention in the form of 
passive oral transfer from hyperimmune colostrum and colostral derivatives 
has shown encouraging results in the treatment of the immunocompromised 
host (Mata, 1986; Tzipori et al., 1986; Ungar et al., 1990b; Plettenberg et al., 1993; 
Shield et al., 1993). Lactogenic transfer, however, continues to be plagued by 
an inconsistent clinical response and the inevitable recrudescence of infection 
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following cessation of therapy (Tzipori, 1983; Moon eta!., 1988; Arrowood and 
Sterling, 1989; Moody eta!., 1991; Tachibana eta!., 1991). Strategies to enhance 
immune responsiveness with immunomodulating substances (i.e., 
dehydroepiandrosterone, azidothymidine, dialyzable leukocyte extracts) have 
shown preliminary success in reducing the severity of infection and indicate a 
potential route for continued therapeutic research (Chandrasekar, 1987; 
Greenberg et a!., 1989; McMeeking et al., 1990; Rasmussen et al., 1992; 
Rasmussen and Healey, 1992a, 1992b). Likewise, cryptosporidiosis in the 
iatrogenically immunosuppressed host is frequently resolved once the 
suppressive therapy is discontinued and immune responsiveness regains 
normal efficacy (Miller et al., 1983; Foot et al., 1990). 
The human immune response to C. parvum infection has been an area 
of considerable research. Studies have demonstrated a significant humoral 
response to C. parvum and have reported the production of antibodies 
directed against antigens expressed in one or more developmental stages 
(Taghi-Kilani et al., 1990; Fayer et al., 1991; Mosier et al., 1992; Nina eta!., 1992; 
Georgiev, 1993; Moss eta!., 1994; Sorvillo et al., 1994). In vitro neutralization 
of surface-expressed epitopes by both monoclonal and polyclonal antibodies 
has been shown to reduce sporozoite and merozoite infectivity, implicating a 
role for acquired antibodies in protection from repeated exposure (Riggs and 
Perryman, 1987; Harp et al., 1989; Bjorneby eta!., 1990; Tilley et al., 1991; Uhl et 
a!., 1992; Perryman et al., 1993; Tilley and Upton, 1994; Harp eta!., 1995). The 
putative role of the cell-mediated immune system, and its various cytokine 
14 
mediators, in the adaptive immune response to C. parvum has received 
considerable attention in the literature. Reconstitution studies in nude and 
SCID mice have shown an ameliorating effect on patent infection following 
the adoptive transfer of human T lymphocytes, bone marrow cells, or cells of 
lymph node origin (Mead et al., 1991; Whitmire and Harp, 1991; Harp et al., 
1992; Moss and Lammie, 1993; Cozon et al., 1994). Several studies have 
shown that the depletion of differentiated effector cells such as NK cells, CDS 
T lymphocytes, and CD4 T lymphocytes alters the course of infection in 
laboratory models (Ungar et al., 1990b; Harp and Moon, 1991; Ungar et al., 
1991; Kuhls et al., 1992; Boher et al., 1994; McDonald et al., 1994; Mead et al., 
1994; Perryman et al., 1994). There is, however, evidence to suggest an 
absence of measurable effects on resistance following selective depletion of 
effector cells (Harp and Whitmire, 1991; Ungar et al., 1991; Rasmussen and 
Healey, 1992b; Chen et al., 1993a; Harp et al., 1995). Reduced levels of 
interferon gamma (IFN-y) and interleukin-2 (IL-2) have been shown to 
contribute to enhanced murine infection (Ungar et al., 1991; Chen et al., 1993a, 
1993b). Clearly, the mutual contributions of both the humoral and cell-
mediated adaptive immune responses are intimately associated with 
eradication of cryptosporidial infection and formation of protective 
immunity to subsequent challenge (Heyworth, 1990; Tachibana et al ., 1991; Zu 
et al., 1992; McDonald and Bancroft, 1994; Mead et al., 1994; Harp et al., 1995). 
It is also apparent that the immune response to cryptosporidiosis is a 
complex, and largely unresolved, process. 
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Anecdotal evidence suggesting an age-related susceptibility to 
cryptosporidiosis in humans most likely reflects a lack of immunologic 
maturity of the host at the time of primary exposure (MacFarlane and 
Homer-Bryce, 1987; Daoud eta!., 1990; Tangermann eta!., 1991; Kuhls eta!., 
1992). Notwithstanding the significance of underlying physiological changes 
during the first several years of human development, it is probable that 
maturation of the neonatal immune system accounts for the progressively 
enhanced resistance to C. parvum infection observed in adolescence and 
adults (Fripp eta!., 1991; Zu eta!., 1994). 
The innate, nonspecific, nonadaptive defense mechanisms of the 
human system are largely unexplored in regard to Cryptosporidium infection. 
Reports of the beneficial effects of normal gut microflora in resisting C. 
parvum infection in mice and the observation of anticryptosporidial activity 
in nonimmune colostrum and bovine milk suggest that one or more 
nonspecific factors, outside the parameters defined by the adaptive immune 
response, potentially reduce host vulnerability and morbidity associated with 
C. parvum infection (Brown eta!., 1992; Harp eta!., 1992; Garber eta!., 1994). 
At present, the dynamics of early cryptosporidial infection and host defenses 
against invasive stages of the organism are not fully understood. 
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Alpha-1-antitrypsin 
Alpha-1-antitrypsin (AAT) is a single chain glycoprotein composed of 
394 amino acid residues with a molecular weight of approximately 56 kDa 
(Travis and Salvesen, 1983). AAT is one of a group of human serine protease 
inhibitors (serpin) found in peripheral circulation and tissue fluids. 
Collectively, the serpin family provides intrinsic regulation of proteolytic 
activity from endogenous proteases (Baumstark, 1967; Joslin et a!., 1993). 
These inhibitors are particularly active during periods of acute inflammation 
and are substantive components of the "acute phase" plasma protein 
response elicited during the inflammatory process (Travis and Salvesen, 1983; 
Carrell and Travis, 1985; Whicher eta!., 1993; Potempa eta!., 1994). In the 
human system, AAT inhibits excessive protease-mediated tissue destruction 
from neutrophil elastase and provides systemic protection from enzymatic 
degradation in adjacent tissues (Cohen, 1975; Beatty eta!., 1980; Carrell, 1986; 
Castellucci eta!., 1994). 
The AAT glycoprotein undergoes a dramatic increase in hepatocellular 
synthesis during acute inflammation. This episodic production is primarily 
mediated by the cumulative interactions of interleukin-1 (IL-l) and 
interleukin-6 (IL-6) and manifests itself in serum concentrations several 
magnitudes greater than those observed in the normal, noninflammatory 
state (Koj eta!., 1993; Perlmutter, 1993; Potempa eta!., 1994; Kanakoudi eta!., 
1995). While the primary source of systemic AAT is of hepatic origin, 
increasing evidence supports the synthesis and release of supplemental AA T 
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from extrahepatic sources. Reports of enhanced AAT synthesis in response to 
inflammatory cytokines have been attributed to mononuclear cells from 
peripheral circulation and intestinal epithelial cell lines in culture 
(Perlmutter eta!., 1989, 1990; Molementi eta!., 1993). Perlmutter and his 
colleagues (1989) first demonstrated the synthesis and secretion of AAT in 
response to IL-6 stimulation in a human adenocarcinoma colonic epithelial 
cell line (Caco-2). Molementi eta!. (1993) confirmed IL-6-induced AAT 
production in the differentiated Caco-2 cell line and also measured AAT 
synthesis in the undifferentiated enterocytic form of the Caco-2 cell line. 
These investigators further demonstrated AA T synthesis in the human 
intestinal epithelial cell line T84, another undifferentiated (crypt-like) cell 
line, induced by the additive and synergistic action of IL-l and IL-6. These 
findings potentiate an in vivo mechanism for AAT synthesis and secretion in 
the human intestinal tract independent of crypt-to-villus differentiation. 
Alpha-1-antitrypsin performs its inhibition action through the 
formation of a 1:1 molecular complex with a serine protease (Baumstark, 
1967; Carrell, 1986). The reactive site of AAT, Met358:ser359, interacts with 
the active site of the target enzyme and blocks proteolytic activity by the 
bound enzyme. In effect, AAT acts as a substrate analog for the cognate 
enzyme. The serpin:enzyme complex (SEC) formed by the reactive site 
interactions demonstrates high affinity in its binding association under 
physiological conditions, primarily as a result of covalent attractions between 
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the serpin and its cognate enzyme (Perlmutter eta!., 1990; Herve and Ghelis, 
1991; Joslin eta!., 1993). The AAT reactive site loop imparts a degree of 
functional specificity to the molecule; this portion of the molecule must 
closely mimic the physiochemical properties of an appropriate substrate to 
achieve serpin:protease recognition (Perlmutter, 1993). The SEC is rapidly 
cleared from circulation and both molecules are physically eliminated from 
further enzymatic activity (Carrell, 1986; Joslin eta!., 1993). 
There is considerable evidence of a minor structural rearrangement of 
the AA T molecule following complex formation with neutrophil elastase. 
Cleavage of the complexed serpin at the methionine reactive site releases the 
stressed configuration of the reactive site loop and exposes a small 
(pentapeptide) sequence of the AAT protein (Perlmutter eta!., 1990; Joslin et 
a!., 1991; Perlmutter, 1993). This exposed peptide fragment includes the 
carboxyl terminal portion of the protein and has been attributed a functional 
role in signaling upregulation of AA T synthesis in cells bearing a specific SEC 
receptor (Perlmutter eta!., 1989). This mechanism of enhanced serpin 
synthesis following inhibition of a target protease (i.e., elastase) and 
recognition of the resulting complex by a SEC-specific receptor is a 
homeostatically relevant mechanism in the balance of elastase and anti-
elastase activity in humans. Additionally, the SEC possesses neutrophil 
chemotactic properties and serves as an adjunct to other migration/attraction 
signals expressed during inflammation or tissue injury (Travis and Salvesen, 
1983; Banda eta!., 1988). Thus, the native AAT molecule demonstrates 
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functionally specific inhibitory activity and the structurally altered molecule 
in the SEC formation, specifically the carboxyl terminus associated 
pentapeptide, exhibits a relatively broad range of biological effector properties 
that enhance the process of inflammation in humans. 
The literature contains very few previous examples of interactions 
between AAT and parasitic pathogens. Lushbaugh et al. (1981) reported the 
inhibition of Entamoeba histolytica cytotoxin, a proteolytic enzyme thought 
to account for the amoeba's aggressive tissue invasion, by AAT and the alpha-
2-macroglobulin (A2M) protein complex. A2M and, to a lesser extent, AAT 
were shown to inhibit tissue invasion of E. histolytica trophozoites. Further 
analysis revealed the isolated protein cytotoxin-enterotoxin to be a cysteine 
protease with a high sequence homology to papain-like enzymes; the trivial 
name "amiebapain" has been suggested for the enzyme (Stanley et al., 1995). 
Modha and Doenhoff (1994a) reported the formation of complexes 
between human AAT and surface membrane components of Schistosoma 
spp cercariae. Their results substantiate previous reports of serine protease 
expression in schistosomes. The nature of the reported interaction, 
presumably AAT binding to surface protease enzymes, suggests the basis for a 
nonspecific host defense mechanism against exogenous protease activity 
introduced by the invading schistosomule. The AAT:schistosome 
interactions described by these investigators were further implicated as an 
example of immune evasion by antigenic mimicry; the formation of AAT 
complexes with surface-expressed parasite proteases blocks the 
conformational availability of these immunogenic proteins to immune 
effector cells. A parasite coated by host endogenous serpin proteins could 
potentially evade host immune recognition (Modha and Doenhoff, 1994b). 
Proteases in coccidian parasites 
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The role of natural and synthetic inhibitors in mediating the effects of 
exogenous parasitic proteases is an area of active investigation. Key to this 
research interest is the essential role of proteolysis in living cells and the 
potential parasiticidal effects that could be achieved by interfering with 
parasite protease at;tivity. Proteolytic activity has been described in the 
invasion, infectivity, and pathogenicity of many parasitic pathogens. 
Protease-mediated events facilitate host cell attachment (Arroyo and Aldrete, 
1989), membrane penetration (Hadley et al., 1983; Adams and Bushell, 1988; 
Fuller and McDougald, 1990), tissue migration (Modha et al., 1988; Modha and 
Doenhoff, 1994a; Morris and Sakanari, 1995; Yenbuter and Scott, 1995), and 
degradation of host proteins for use as a nutrition source (Chappell and 
Dresden, 1986), and serve as a potential mechanism to elude host immune 
responses (Marikovski et al., 1988; Malzels et al., 1993; Modha and Doenhoff, 
1994b). 
The majority of protozoan proteases described in the literature are of 
the cysteine protease class (Coombs and North, 1991; North, 1992; McKerrow 
et al., 1993). Serine protease activity has been demonstrated in several 
parasitic species, but isolation and characterization of this class of enzymes 
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have not been as frequently reported. Further, it is quite reasonable to 
speculate that many protozoa may express multiple proteolytic enzymes of 
various classes, either simultaneously or in a developmental-stage specific 
fashion. A particularly difficult obstacle to overcome in working with 
protozoan enzymes is the low levels of protein recovery from organisms and 
the diverse number of life-cycle stages found in some species. Latency (i.e., 
expression of precursor enzyme forms) and autocatalytic properties further 
hamper efforts to isolate and characterize enzyme activity. 
Within the phylogenetic scheme Apicomplexa:Coccidia:Eucoccidiida, 
protease enzyme identification and characterization have primarily focused 
on Plasmodium spp. A number of malarial proteases have been described, 
both by isolation as well as by the demonstration of proteolytic activity. The 
initial report of protease activity in malaria appeared 50 years ago (Moulder 
and Evans, 1946), and now over 15 distinct proteolytic enzymes have been 
reported (reviewed in Coombs and North, 1991). Proteases have been 
reported as critical factors in erythrocyte invasion/ reinvasion (Rosenthal et 
a!., 1987; McKerrow eta!., 1993), cell rupture (Bernard and Schrevel, 1987; 
Grellier et a!., 1989), and hemoglobin degradation for nutrition (Sherman and 
Tanigoshi, 1981, 1983; Rosenthal eta!., 1989). Of particular interest is the 
report of a malarial protease that exhibits an inhibitor sensitivity pattern 
suggesting serine and cysteine protease properties in a single enzyme 
(Dluzewski et a!., 1986). 
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Michalski eta!. (1994) isolated and partially characterized a serine 
protease from homogenized sporulated Eimeria tenella oocysts. This study 
cited the presence of both serine and cysteine protease activity in E. tenella 
oocysts. Multiple proteases have been reported in a number of parasitic 
genera, including Entameoba, Plasmodium, Tricho monas , Trypanasoma, and 
Leishmania (McKerrow et a!., 1993). The phylogenetic relationship between 
Eimeria and Cryptosporidium spp. suggests an analogous pattern of 
proteolytic enzyme activity may exist in cryptosporidial oocysts. 
Only recently has enzymatic activity been described in C. parvum. 
Okhuysen et a!. (1994) demonstrated arginine aminopeptidase (AP) enzyme 
activity associated with the sporozoite membrane and suggested a role for 
aminopeptidase activity in facilitating oocyst excystation. Nesterenko et a!. 
(1995) reported cysteine protease activity associated with solubilized 
membrane fractions of excysted sporozoites and proposed an association 
between enzyme activity and host cell infection. Inhibition of proteolytic 
enzymes in coccidian parasites, notably in Eimeria spp and Plasmodium spp., 
by natural and synthetic serine protease inhibitors has shown a significant in 
vitro reduction in cell infectivity (Hadley eta!., 1983; Adams and Bushell, 
1988; Fuller and McDougald, 1990). It has now been shown that C. parvum 
expresses protease activity, evidenced by azocasein hydrolysis, during peak 
periods of excystation (Forney et a!., 1996c). Further, serine protease inhibitors 
significantly antagonize excystation of oocysts and reduce in vitro infectivity 
(Forney eta!., 1996a, 1996d, 1997). Unlike Nesterenko's report of a cysteine 




The studies comprising this dissertation hypothesized the expression of 
serine protease activity in one or more of the developmental stages of C. 
parvum. It was further hypothesized that AAT, as the major serine protease 
inhibitor in human circulation, could be an active component of an innate, 
nonspecific defense mechanism against C. parvum infection. The specific 
emphasis of these related postulates generated four research objectives: 
1. Evaluate C. parvum for the expression of serine protease-like activity. 
2. Determine if serine protease expression is a stage-specific characteristic of C. 
parvum. If so, identify the developmental stage(s) that express serine 
protease activity. 
3. Locate the site(s) of serpin complex formation on, or within, the C. 
parvum organism. 
4. Evaluate the in vitro anticryptosporidial potential of protease inhibitors. 
These objectives represented an opportunity to expand the current 
knowledge of the immunobiology of C. parvum and explore the relationship 
between protease activity and infectivity. Localization of AAT interactions 
with specific developmental stages of the parasite demonstrated the 
expression of serine protease-like activity on the surface of freshly excysted 
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sporozoites. Further, the capability of AAT, and other protease inhibitors, to 
antagonize oocyst excystation and alter the infection dynamics of C. parvum 
has provided a scientific basis to support the investigation of natural and 
synthetic protease inhibitors as potential chemotherapeutic agents in the 
treatment of cryptosporidiosis. 
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INTERACTION OF THE HUMAN SERINE PROTEASE INHIBITOR 
ALPHA-I-ANTITRYPSIN WITH CRYPTOSPORIDIUM PARVUM1 
ABSTRACT: The protozoan parasite Cryptosporidium parvum was 
studied for interaction with a human serine protease inhibitor (serpin), 
alpha-1-antitrypsin (AAT). A C. parvum homogenate (CPH) prepared from 
oocysts was incubated with purified human AAT, and complexes formed 
between the serpin and CPH were detected using an enzyme-linked 
immunosorbent assay (ELISA). The optical density read at 450 nm of 
AAT:CPH reactivity was significantly increased (P < 0.001) relative to CPH in 
the absence of AAT treatment. Additionally, ELISA reactivity was blocked by 
incubating AAT with a cognate target enzyme, porcine pancreatic elastase 
(PPE), prior to treatment of the CPH. Incubation of a partially excysted sample 
of C. parvum with AAT (37°C X 60 min) demonstrated preferential 
fluorescence labeling of sporozoites by indirect immunofluorescence assay; 
AAT complexes were not detected on intact oocysts. Localization of AAT 
interactions with C. parvum sporozoites was visualized by transmission 
immunoelectron microscopy. Collectively, these data suggest that C. parvum 
sporozoites express a protease- like component that is recognized by human 
AAT. The ability to block ELISA reactivity with PPE suggests that the AAT 
interactions we detected are functionally similar to the serpin:enzyme 
complex AAT forms with a protease target. 




Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is a 
parasitic agent of diarrheal illness. This protozoan preferentially invades the 
epithelial cells lining the microvilli of the small intestine and causes a 
generally self-limited diarrhea in otherwise healthy individuals (Fayer et a!., 
1990). Spontaneous eradication of the parasite from the intestinal mucosa 
and protective acquired immunity is the general outcome of infection in the 
immunocompetent individual (O'Donoghue, 1995). The most severe 
consequence of cryptosporidiosis occurs in the immunodeficient host. These 
individuals frequently develop a profuse, protracted diarrheal illness which 
progresses to a chronic patent infection of the intestinal epithelium (Gellin 
and Soave, 1992; Phillips et a!., 1992) and, potentially, cryptosporidial 
dissemination into the alveolar and tracheal epithelium (Petersen, 1992; 
Giang eta!., 1994; Mifsud eta!., 1994). 
Protease activity has been described in the invasion, infectivity, and 
pathogenicity of several parasitic diseases. Protease-mediated events facilitate 
host cell attachment (Adams and Bushell, 1988; Arroyo and Aldrete, 1989), 
membrane penetration (Hadley eta!., 1983; Fuller and McDougald, 1990), 
degradation of host proteins for use as a nutrition source (Chappell and 
Dresden, 1986), tissue migration (Modha eta!. , 1988; McKerrow eta!., 1990; 
Modha and Doenhoff, 1994b; Morris and Sakanari, 1995; Yenbuter and Scott, 
1995), and parasite maturation and development (Richer et a!., 1993), and 
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provide a potential mechanism to elude host immune responses (Malzels et 
a!., 1993; Modha and Doenhoff, 1994b). 
Alpha-1-antitrypsin (AAT) is one of a group of human serine protease 
inhibitors (serpin) found in peripheral circulation and tissue fluids. 
Collectively, the serpin family provides an intrinsic defense mechanism to 
regulate proteolytic activity from endogenous proteases (Baumstark, 1967; 
Carrell and Travis, 1985; Joslin eta!., 1993). These inhibitors are particularly 
active during periods of acute inflammation and are a substantive 
component of the "acute phase" plasma protein response elicited during the 
inflammatory process. AAT undergoes a dramatic increase in hepatocellular 
synthesis that manifests itself as serum concentrations several magnitudes 
greater than normally present in peripheral circulation (Travis and Salvesen, 
1983; Whicher et a!., 1993; Potempa et a!., 1994). In the inflammatory setting, 
AAT inhibits excessive protease-mediated tissue destruction from leukocyte 
elastase and provides systemic protection from enzymatic degradation in 
adjacent tissues (Beatty et a!., 1980; Travis and Salvesen, 1983; Huber and 
Carrell, 1989). 
The specific objective of the present study was to examine C. parvum 
for a serine protease-like component capable of recognition and functional 
interaction with human AAT. Immunolocalization of the resulting 
interactions was performed to determine if AAT-recognized protease-like 
activity was expressed as a constitutive component of both oocysts and 
sporozoites of C. parvum or if differential expression limited detection to 
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only one of these stages. Here we report the detection of AAT complexes 
formed with components of a cryptosporidial homogenate by an enzyme-
linked immunosorbent assay (ELISA). Further, a combination of indirect 
immunofluorescence labeling and colloidal gold immunoelectron 
microscopy localized AAT complexes on the sporozoite stage of C. parvum. 
MATERIALS AND METHODS 
Parasite propagation and isolation 
Oocysts were maintained by passage in experimentally infected 
Holstein calves and purified from feces using discontinuous sucrose and 
isopycnic Percoll gradients (Arrowood and Sterling, 1987). Purified oocysts 
were stored in 2.5% potassium dichromate (KzCrz07) at 4°C until used. 
Oocysts, stored less than 90 days, were decontaminated with a 10% (v /v} 
bleach solution for 10 min at 4°C and washed thoroughly with sterile Hanks' 
balanced salt solution (HBSS) to remove residual bleach and KzCrz07. 
Decontaminated oocysts were harvested following centrifugal concentration 
and resuspended in sterile HBSS or phosphate buffered saline (PBS) prior to 
use in assay protocols. 
Preparation of parasite oocysts and 
sporozoites 
A mixture of intact oocysts and freshly excysted sporozoites was 
prepared for use in immunolocalization assays. A purified suspension of C. 
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parvum oocysts in PBS was allowed to excyst for 90 min (37°C /5% COz) in the 
absence of any further treatment (Bonnin et a!., 1991; Robertson eta!., 1993). 
Excystation efficacy was monitored by light microscopy. In some studies, 
purified oocysts were freeze-thaw permeabilized prior to immunolabeling. 
Preparation of parasite homogenate 
A 5-ml suspension of 1Q6 oocysts / ml in 25 mM PBS was sonicated 5 X 
45 seconds (50 mW) on ice to produce the C. parvum homogenate (CPH) used 
in subsequent ELISA protocols. CPH prepared in this fashion was assayed for 
total protein concentration (Bicinchonimic Acid Protein Assay, Pierce 
Scientific, Rockford, Illinois) and typically yielded total protein values in the 
range of 150-200 ~g/ml. CPH was stored at -20°C prior to use. 
ELISA 
A modified ELISA was used to detect AAT interactions with CPH. A 
100-Jll aliquot of CPH was added to test wells in 96-well flat bottom 
polystyrene microtiter plates (Corning Glass Works, Corning, New York) in 
the presence of a carbonate coating buffer, pH 9.4. Immobilization was 
performed overnight at 4°C. Coated plates were washed with PBS/ 0.05% 
Tween 20 (PBST) and blocked with 1% gelatin / PBST for 4 hr at 25°C. The 
blocked plates were washed with PBST and 100 Ill of a 50 Jlg/ ml dilution of 
purified human AAT (Sigma Chemical Company, St. Louis, Missouri) was 
added to each test well. The plates were incubated for 60 min at 37°C. The 
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interaction between AAT and components of the immobilized CPH provided 
a stabilized antigen for an indirect (2 antibody) ELISA (Crowther, 1995). 
Subsequent steps were conducted at 37°C and were followed by PBST washing. 
A 100-J.!l aliquot of 1:100 rabbit anti-human AAT, IgG fraction, (Sigma) was 
added to test wells and incubated for 30 min. A 1:2000 dilution of horseradish 
peroxidase (HRPO)-conjugated goat anti-rabbit IgG (Sigma) was then added to 
test wells (100 Jll), followed by a 30 min incubation period. Plates were 
washed a final time with PBST and 100 Jll of 4% 0-phenylenediamine (OPD) 
dihydrochloride/0.02% hydrogen peroxide was added to each well. The plates 
were then incubated for 10 min at 25°C and protected from light. Antibody 
binding and ELISA reactivity was interpreted as an increase in optical density 
measured at 450 nm (OD4so) (Microplate Autoreader, Bio-Tek Instruments, 
Inc., Winooski, Vermont) relative to control wells containing immobilized 
CPH, but untreated with human AAT. Variation between OD450 values was 
examined for statistical significance utilizing 2-tailed t-test analysis and 
simple analysis of variance (ANOVA) on a STATVIEWTM data analysis 
program (Haycock eta!., 1992). 
Blocking studies were performed using porcine pancreatic elastase 
(PPE), a cognate target enzyme of AAT, to evaluate the functional specificity 
of AAT complexes formed with components of CPH. PPE binds covalently to 
the AAT molecule and occupies its reactive site loop, thereby eliminating the 
potential for further inhibitor activity by the bound serpin (Joslin et a!., 1991, 
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1993; Perlmutter, 1993). PPE was mixed with AAT in varying molar ratios 
and the protease-serpin mixture was incubated 60 min at 37°C. The PPE-
treated AAT was then added to gelatin-blocked, CPH-coated test wells and the 
ELISA completed as described. OD450 values for PPE-blocked ELISA studies 
were compared to AA T:CPH reactivity in the absence of PPE treatment for 
statistically significance differences. 
Immunofluorescence microscopy 
A partially excysted mixture of oocysts and sporozoites was added to 
each well of a 10-w~ll immunofluorescence glass slide, air-dried at 25°C, and 
heat-fixed. All subsequent steps were performed at 37°C in a humidity 
chamber and separated by thoroughly washing with PBST. Each sample was 
incubated successively in purified human AAT (50 J.tg/ ml X 60 min), rabbit 
anti-human AAT, IgG fraction, (1 :100 X 30 min), and fluorescein 
isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (1 :100 X 30 min). 
Immunofluorescence assay (IFA) antibodies were obtained from Sigma. 
Slides were again washed with PBST, covered with a nondrying mounting 
medium, and examined by epifluorescence microscopy. Related studies 
utilized freeze-thaw permeabilized oocysts as the initial sample with all 




Pre-embedding immunogold labeling: To emphasize surface labeling, a 
mixture of intact oocysts and free sporozoites was fixed with 0.5% 
glutaraldehyde in PBS at 4ac for 10 min and labeled as described by Sibley and 
Sharma (1987) for transmission electron microscopy (TEM). In brief, the 
lightly fixed parasites were washed in cold PBS and incubated successively in 
human AAT (50 J.lg /ml X 60 min), rabbit anti-human AAT, IgG fraction (1:20 
X 30 min), and 10 nm colloidal gold-conjugated goat anti-rabbit IgG (1:20 X 30 
min) with each step separated by PBST washing at 4°C. Immunogold labeling 
reagents were obtained from Sigma. Following the immunolabeling 
procedure, parasites were fixed a second time in 0.5% glutaraldehyde at 4°C 
for 20 min and dehydrated in an iced ethanol gradient. Samples were 
impregnated with LR White resin (Electron Microscopy Sciences, Ft. 
Washington, Pennsylvania) at 25°C and polymerized overnight at 60°C in 
gelatin capsules. Thin sections of LR White-embedded samples were 
mounted on nickel grids, carbon-coated, and viewed by TEM (Zeiss 902CEM, 
Thornwood, New York) after contrast-enhanced staining with saturated 
uranyl acetate (4 min at 50°C) and lead citrate (2 min at 25°C). 
Post-embedding immunogold labeling: Samples of a C. parvum 
excystation mixture were fixed with 0.5% glutaraldehyde/2% 
paraformaldehyde in PBS at 4°C for 20 min. Fixed parasites were washed in 
cold PBS, dehydrated in an iced ethanol gradient, and embedded in LR White 
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resin. Thin sections were mounted on nickel grids, carbon-coated, and floated 
for 10 min in PBS / 0.5"/o bovine serum albumin (BSA) / 0.02% Tween 20. The 
samples were washed with PBST and transferred onto human AAT (50 
!!g/ ml) for 60 min at 37°C. Grids were successively floated on rabbit anti-
human AA T, IgG fraction (1:50 in blocking buffer) for 30 min and 10 nm 
colloidal gold-conjugated goat anti-rabbit IgG (1 :20 in blocking buffer) for 30 
min; each step was followed by PBST washing. After the final wash, grids 
were rinsed with water and viewed by TEM after contrast-enhanced staining. 
RESULTS 
Detection of AA T interaction with 
C. parvum 
Figure 2-1 shows the pattern of ELISA reactivity observed for AAT 
interactions with 3 different protein coatings, i.e., BSA, CPH, and PPE. ELISA 
reactivity demonstrated a statistically significant increase (P < 0.001) in optical 
density following incubation of the immobilized CPH with AAT relative to 
immobilized CPH not exposed to AAT. The pattern of reactivity observed for 
AAT-treated C. parvum was consistent with the increase in 00450 values 
observed in reaction wells containing immobilized PPE as an initial antigen 
coating. A concentration-dependent increase in 00450 was apparent 
following AAT incubation with serial dilutions of CPH (Fig. 2-2). Figure 2-3 
shows the blocking effect of PPE on serpin interaction with CPH. A loss of 
AAT:CPH reactivity (OD4so) was measured when AAT was incubated with 
PPE (37°C X 60 min) before adding the serpin to ELISA test wells. 
Immunolocalization of AA T: 
parasite complexes 
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Indirect immunofluorescence labeling: A partially excysted mixture of 
C. parvum oocysts and sporozoites, incubated with human AAT and 
analyzed by an indirect IFA, demonstrated preferential labeling of the 
sporozoite stage of the parasite (Fig. 2-4) . Sporozoites typically exhibited a 
diffuse, moderately intense fluorescence pattern on their surface membrane. 
Intact oocysts did not bind the FITC-conjugated ligand. Figure 2-5 illustrates 
the immunofluorescence labeling pattern observed in freeze-thaw 
permeabilized oocysts incubated with AAT. These samples revealed a 
prominent fluorescence labeling of sporozoites within unexcysted, and 
otherwise unlabeled, oocysts. Collectively, these observations show that AAT 
interactions were limited to C. parvum sporozoites. 
Immunoelectron microscopy: AAT interactions at the ultrastructural 
level were investigated in thin sections of oocysts and sporozoites. 
Immunogold labeling of C. parvum following incubation with AAT 
demonstrated a prominent labeling of the surface of excysted sporozoites; a 
smaller number of gold particles were observed in the intracellular matrix of 
sectioned parasites (Fig. 2-6). As expected, the pattern of surface-associated 
immunogold labeling was particularly well defined when samples were 
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labeled prior to resin impregnation and polymerization. Post-embedding 
labeling of sections through oocysts containing sporozoites showed gold 
particles in association with the sporozoite stages, but in much smaller 
numbers than observed for free sporozoites (Fig. 2-7). Surface-associated gold 
labeling was typically uniform and evenly distributed on free sporozoites; 
there was no discernible pattern of gold particles that would suggest a 
differential gradient of AAT complexes on the sporozoite. 
Cryptosporidium parvum oocysts did not bind the gold-conjugated 
ligand in either the pre- or post-embedding labeling procedures, suggesting a 
lack of AAT interaction with the oocyst wall. As seen in Figure 2-7, small 
clusters of gold particles were occasionally observed within the perimeter wall 
of unexcysted oocysts, but not in direct association with any structural 
element of the internal oocyst wall. 
DISCUSSION 
This study is the first to demonstrate a functional interaction between a 
human serpin (AA T) and components of the sporozoite stage of C. parvum. 
This interaction, presumably the result of complexes formed between AAT 
and parasite proteases, was detected by ELISA (Figs. 2-1, 2-2) and clearly 
observed following IFA (Fig. 2-4). The complexes were further visualized by 
TEM as a developmental stage-specific interaction primarily associated with 
components of the sporozoite surface membrane (Fig. 2-6). Our findings, in 
conjunction with Okhuysen et al.'s (1994) demonstration of arginyl 
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aminopeptidase activity, suggest that C. parvum sporozoites express a serine 
protease-like component that is functionally similar to trypsin (Powers et a!., 
1993). Classified in terms of substrate specificity, the anionic residues forming 
the active site "pocket" of trypsin-like enzymes preferentially hydrolyze 
peptides at cationic amino acid residues, such as arginine or lysine (Craik et 
a!., 1985; Perona eta!., 1993; Powers eta!., 1993; Perona and Craik, 1995). 
Whereas the preponderance of scientific evidence points to neutrophil 
elastase as the primary physiologic target of AAT inhibition (Beatty et a!., 
1980; Gadek eta!., 1981; Huber and Carrell, 1989; Joslin eta!., 1993; Doring, 
1994), the serpin molecule was originally described for its in vitro inhibitory 
effect on trypsin (Mollet a!., 1958; Bundy and Mehl, 1959). 
AAT is a single chain glycoprotein that performs its inhibitory action 
through the formation of a 1:1 molecular complex with a serine protease 
(Perlmutter, 1993). A reactive site loop of the AAT molecule interacts with 
the corresponding active site of a target enzyme and blocks proteolytic activity 
by the bound enzyme; in effect AAT acts as a substrate for the protease. The 
serpin:enzyme complex (SEC) formed by the reactive site interactions 
demonstrates high affinity in its binding association under physiological 
conditions, primarily as a result of covalent attractions between the serpin 
and its cognate enzyme. The AAT reactive site loop imparts a degree of 
functional specificity to the molecule; this portion of the molecule closely 
mimics the physiochemical properties of an appropriate substrate to achieve 
serpin:protease recognition. Once formed, the SEC is rapidly cleared from 
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circulation by specific receptor-mediated endocytosis in the parenchyma of the 
liver (Perlmutter eta!., 1990; Joslin eta!., 1991). 
The ELISA used in this study was designed to detect AAT:C. parvum 
interactions by adapting the functional specificity of AAT to probe CPH for 
protease-like components capable of interacting with the serpin molecule. To 
achieve this end, we exploited 2 characteristics of the SEC. First, the AAT 
molecule forms a very stable complex with a target enzyme Goslin et a!., 1993; 
Stein and Carrell, 1995), stable enough to withstand the manipulations 
accompanying the selected immunoassays. Second, SEC formation is 
accomplished while retaining a relatively intact structural configuration of 
the AAT molecule, thus permitting its detection by immunological 
techniques directed against epitopes on that portion of the glycoprotein 
protruding from the SEC Goslin eta!., 1991; Bjork eta!., 1993). The 
demonstrated loss of ELISA reactivity following pretreatment of AAT with 
PPE (Fig. 2-3) suggests that once elastase occupies the AAT reactive site loop, it 
effectively blocks serpin recognition of analogous structures in the CPH. 
The results of IFA and immunogold labeling show a clear distinction 
in the labeling intensity between free sporozoites and sporozoites within 
intact oocysts. Figure 2-6 illustrates a qualitatively enhanced recognition of 
AAT complexes on freshly excysted sporozoites compared to unexcysted 
sporozoites within otherwise intact oocysts (Fig. 2-7). We postulate that 
serine protease-like components of C. parvum sporozoites are in an 
enzymatically inactive form prior to excystation. In the zymogen 
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(proenzyme) form, protease activity would remain at very low levels until 
activated by one or more conditions that "trigger" excystation. Okhuysen et 
a!. (1994) described enhanced aminopeptidase activity after prolonged 
incubation in conditions favorable to excystation; similarly, we demonstrated 
a qualitatively greater detection of AAT complexes formed with excysted 
sporozoites (Fig. 2-4) and in permeabilized oocysts following incubation with 
AAT at 37°C (Fig. 2-5). Because AAT binds to the active site of a target 
enzyme, SEC formation favors the enzymatically active form of proteases 
(Perlmutter, 1993; Perona eta!., 1993; Perona and Craik, 1995). 
The lack of immunolabeling associated with intact oocysts indicates a 
lack of AAT interaction with the oocyst wall and implies an absence of serine 
protease-like expression on this stage of parasite development. We did 
observe some oocyst sections that contained a small number of gold particles 
within the confines of an intact oocyst wall (Fig. 2-7). This observation may 
reflect the dissociation of AA T complexes from sporozoites as an artifact of 
the fixing, sectioning, and labeling process. Conversely, intraoocyst gold 
conjugate may indicate that metabolically active sporozoites undergo low-
level expression and shedding of protease-like components while sequestered 
within an intact oocyst. 
There is substantial evidence of a structural rearrangement of the AA T 
molecule following complex formation with a protease target that presents a 
small (pentapeptide) sequence of the AAT protein (Perlmutter eta!., 1990; 
Perlmutter, 1993; Stein and Carrell, 1995). This exposed peptide fragment 
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includes the carboxyl terminal sequence of the protein and has been attributed 
a functional role in signaling upregulation of AAT synthesis in cells bearing a 
specific SEC receptor (Schreiber and Aldred, 1993; Perlmutter, 1993; Potempa 
et a!., 1994). We speculate that a protease-like component expressed by C. 
parvum sporozoites may help upregulate AAT levels mediated by specific 
receptor recognition of SEC complexes. Though lacking parasite specificity, 
this primitive defense mechanism may afford protection against proteolytic 
activity during the course of early infection and minimize host vulnerability 
to exogenous proteases while an adaptive immune response is being 
mounted against the parasite. An interesting association is apparent given 
the in vitro demonstration of an "acute phase" protein response in 
extrahepatic sites (Molementi eta!., 1993; Perlmutter, 1993). These 
observations, in particular Molementi's demonstration of AAT production in 
human intestinal epithelial cells, suggest the possibility of a self-amplifying 
serpin response to cryptosporidial proteases sustained by upregulation of 
AAT synthesis in the immediate vicinity of parasitic infection. While the 
potential for local (i.e., intestinal epithelium) AAT production may exist as a 
homeostatic response to exogenous proteases, a recent study reported a lack of 
correlation between the intensity of cryptosporidial infection and fecal AAT 
clearance (Goodgame eta!., 1995). The influence of extrahepatic AAT 
production in intestinal parasitic infections is yet to be fully defined. 
The role of protease inhibitors in abrogating the effects of exogenous 
parasite proteases is an area of active investigation. This class of regulatory 
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proteins has been reported to reduce intraerythrocytic stages of Plasmodium 
vinckei in mice (Rosenthal et al., 1993); affect the maturation and 
development of Trypanosoma spp (Meirelles et a!. , 1992), Strongyloidies 
stercora/is (McKerrow eta!., 1990), and Dirofilaria immitis (Richer et a!., 1993); 
and reduce the in vitro infectivity of Eimeria spp (Adams and Bushell, 1988; 
Fuller and McDougald, 1990; Cohen eta!., 1991). Modha and Doenhoff (1994a) 
reported the formation of complexes between human AAT and surface 
membrane components of Schistosoma spp cercariae. Their data suggest a 
putative role for human serpin activity during schistosoma! infection. The 
nature of the reported interaction, AAT binding to parasite proteases, suggests 
that a nonspecific defense mechanism against exogenous parasite proteases 
facilitates the homeostatic balance between protease and anti-protease activity. 
Modha and Doenhoff further suggested (1994b) that schistosome interactions 
with circulating serpin molecules are an example of immune evasion by 
antigenic mimicry. The formation of AAT complexes with surface-expressed 
proteases blocks the conformational availability of these immunogenic 
parasite proteins to immune effector cells. A foreign organism coated by 
endogenous host serpin proteins could potentially evade immune 
recognition. 
Bristow et a!. (1995) recently demonstrated a cell surface adhesion and 
fusion mechanism between a viral pathogen and host target cells involving 
recognition between serine protease-like receptors and corresponding 
structures analogous to serpin reactive sites. The search for comparable 
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surface adhesins with regard to C. parvum recognition of host epithelial cells 
and subsequent membrane fusion may elucidate the early invasion sequence 
of this parasite. It is conceivable that cryptosporidial protease-like 
components are involved in interactions at the host cell membrane level 
such as has been demonstrated with related coccidians (Adams and Bushell, 
1988; Fuller and McDougald, 1990). Several investigators have reported a 
putative role for surface-expressed glycoproteins or lectin-associated 
membrane affinity to aid in the initial attachment of C. parvum sporozoites 
to host cells (Bonnin et al., 1991; Tilley et al., 1991; Petersen et al., 1992; 
Mitschler et al., 1994; Tilley and Upton, 1994). The initial adherence of 
sporozoites to host cell membranes may facilitate the spatial orientation of 
parasite proteases that further enhance cell attachment and, potentially, 
contribute to the parasite's unique intramembranous location within infected 
cells. 
This study demonstrated a functional interaction between human 
AAT and a protease-like component of the initial invasive stage of C. 
parvum, the sporozoite. This interaction was predominately associated with 
the outer surface of excysted sporozoites; AA T complexes were not detected 
on either the internal or external surface of the oocyst wall. These findings 
suggest that the putative role of human AAT in regulating exogenous 
protease activity should include a protease-like component expressed by C. 
parvum. It would be of particular interest to evaluate the anticryptosporidial 
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potential of serpin compounds by studying the effects of AAT on C. parvum 
infection in permissive cell culture systems and laboratory animal models. 
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Figure 2-1. Pattern of ELISA reactivity for alpha-1-antitrypsin interactions 
with 3 different coating proteins. Cryptosporidium parvum homogenate 
(CPH), porcine pancreatic elastase (PPE), and bovine serum albumin (BSA) 
were used to coat ELISA test wells prior to incubation with alpha-1-
antitrypsin (AAT). ELISA reactivity for wells coated with CPH and PPE was 
significantly greater (P < 0.001) than values determined for untreated wells 
and for the BSA control. The data reflect 2 experiments containing a total of 4 
replicates of BSA and 12 replicates each for wells coated with CPH and 
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Figure 2-2. Concentration-dependent reactivity of alpha-1-
antitrypsin:Cryptosporidium parvum homogenate interactions. OD450 
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values for AAT:CPH (-• -) increased proportional to increases in the 
concentration of CPH [total protein]. Controls consisted of CPH without 
exposure to AAT, treated with either phosphate buffered saline (-o-) or 2% 
(w / v) bovine serum albumin (-• -) in place of the serpin. The data represent 
2 experiments of 2 replicates each for control values and 4 replicates each for 
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Figure 2-3. Effects of porcine pancreatic elastase pretreatment of alpha-1-
antitrypsin on ELISA reactivity. Blocking was demonstrated by pretreating 
AAT with PPE prior to incubation of C. parvum homogenate (CPH) (-e-). 
OD450 values for AAT:CPH reactivity decreased in response to an increase in 
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the ratio of [PPE] to [AAT] . Test wells containing bovine serum albumin 
(BSA) as a coating antigen (-D-) were unaffected by PPE blocking. 
Substituting phosphate buffered saline (PBS) for PPE in the pretreatment step 
(-o-) resulted in a slower loss of ELISA reactivity, suggesting a dilution effect 
on [AAT]. The data reflect 2 experiments of 4 replicates for each test well 
containing CPH and duplicate values for the BSA control. Data are presented 
as the mean ± SO. 
Figure 2-4. Indirect immunofluorescence microscopy of alpha-1-antitrypsin 
interactions with Cryptosporidium parvum. Uniform fluorescence labeling 
was evident on the surface of excysted sporozoites following AAT exposure 
(arrow). Note the absence of FITC-conjugated ligand on the oocyst wall 
(arrowhead) . Scale bar= 10 IJ.m. 
68 
Figure 2-5. Irnrnunolabeling of perrneabilized oocysts. Freeze-thaw 
perrneabilized oocysts incubated with AAT were permissive to 
immunolabeling of serpin complexes formed with sequestered sporozoites 
(arrow); the oocyst wall remained refractory to AAT interaction. Scale bar= 




Figure 2-6. Transmission immunoelectron micrograph of Cryptosporidium 
parvum sporozoites following incubation with alpha-1-antitrypsin. 
Immunodetection of AAT interactions with C. parvum at the ultrastructural 
level is shown by the dense gold labeling on the surface of excysted 
sporozoites. Scale bar = 350 IJ.m. 
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Figure 2-7. Transmission electron micrograph of alpha-1-antitrypsin 
interactions with encysted Cryptosporidium parvum sporozoites. An 
ultrathin section of an intact oocyst containing longitudinal and transverse 
sections through the sporozoites is observed. A minimal number of gold 
particles are seen on the sectioned sporozoites following incubation with 
AAT (arrow). A few small clusters of gold particles are present within the 
confines of the oocyst wall (arrowhead), suggesting the low-level secretion of 
a protease-like component by sequestered sporozoites or shedding of the 
serpin:enzyme complex during labeling. Scale bar= 235 Jlm. 
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CHAPTER 3 
PROTEASE ACTIVITY ASSOCIATED WITH EXCYSTATION OF 
CRYPTOSPORIDIUM PARVUM OOCYSTS1 
ABSTRACT: A Cryptosporidium parvum homogenate (CPH), 
prepared from partially excysted oocysts, was examined for proteolytic activity 
capable of hydrolyzing azocasein. Protease activity, measured at pH 7.0, was 
not detected in fresh oocysts, but increased progressively with incubation at 
37°C. Activity peaked after 60 min incubation, but progressively decreased 
with extended incubation intervals. Cryptosporidial protease activity was 
significantly inhibited (P < 0.01) by the serine protease inhibitors 
phenylmethylsulfonyl fluoride (PMSF), diisopropyl fluorophosphate (DIFP), 
aprotinin, alpha-1-antitrypsin (AAT) and the cysteine protease inhibitor L-
trans-epoxysuccinyl-leucylamindo-(4-guanidino)-butane (E-64). No single 
inhibitor completely blocked CPH-associated protease activity; however, the 
combination of PMSF and E-64 inhibited >95% of the azocasein hydrolysis 
measured in untreated control samples. The same group of inhibitors were 
further evaluated for their ability to inhibit excystation of C. parvum oocysts. 
PMSF, DIFP, aprotinin, and AAT significantly inhibited (P < 0.05) oocyst 
excystation at 15-, 30-, and 60-min incubation intervals; E-64 had no 
significant inhibitory effect on excystation. The results of this study 
demonstrate proteolytic activity during peak periods of excystation. Further, 
we showed that cryptosporidial protease activity was sensitive to both serine 
and cysteine protease inhibitors, but only serine protease inhibitors 
'Coauthored by). R. Forney, 5. Yang, and M. C. Healey. 1996. journal of Parasitology 82: 889-
902. 
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significantly inhibited oocyst excystation. These findings provide preliminary 
evidence of cryptosporidial proteases of both serine and cysteine protease 
classes and suggest that serine protease(s) are functionally associated with 
excystation. 
INTRODUCTION 
Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is a 
protozoan parasite that preferentially invades epithelial cells lining the 
microvilli of the small intestine (Payer et a!., 1990; O'Donoghue, 1995). The 
most severe consequence of human cryptosporidiosis occurs in the 
immunodeficient host; C. parvum is an opportunistic pathogen of substantial 
morbidity in the acquired immunodeficiency syndrome (AIDS) patient 
population. The immunocompromised host develops a profuse, watery 
diarrheal illness which may progress to a chronic, patent infection of the 
intestinal epithelium (Gellin and Soave, 1992; Goodgame eta!., 1995). The 
chronicity and severity of cryptosporidiosis are accentuated by the lack of 
therapeutic agents capable of eradicating the parasite. 
The infective stage of C. parvum is the oocyst, a thick-walled, double-
layered structure containing 4 sporozoites. The intact oocyst is particularly 
resistant to environmental stress, chemical disinfectants, and many 
municipal water purification processes (Campbell et a!., 1982, 1993; MacKenzie 
et a!., 1994; CDC, 1995). Sporozoites excyst from the oocyst following ingestion 
and attach to the intestinal microvilli; parasite development proceeds within 
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an enigmatic residence, an intracellular, but extracytoplasmic, 
parasitophorous vacuole. A small proportion (approximately 20%) of the 
oocysts produced in an infected host are ensheathed within a thin, single 
layer outer wall. This thin-walled oocyst undergoes endogenous sporulation 
and rapidly excysts in the intestinal lumen, accounting for the autoinfective 
cycle observed in chronically infected hosts (Current and Garcia, 1991; Chui 
and Owen, 1994; O'Donoghue, 1995). The characteristics of early 
cryptosporidial infection, including excystation, are an area of active 
investigative effort. Studies have identified conditions that favor excystation 
and reported protocols to optimize in vitro sporozoite production (Robertson 
eta!., 1992, 1993; Upton eta!., 1994); however, the biochemical processes that 
facilitate the emergence of sporozoites from an infective oocyst remain largely 
undefined . 
Recently, investigators have described arginyl aminopeptidase activity 
(Okhuysen eta!., 1994) and a putative cysteine proteinase (Nesterenko et a!. , 
1995), both associated with the outer membrane of sporozoites. Our previous 
study detected an interaction between the human serine protease inhibitor 
alpha-1-antitrypsin (AAT) and the surface of excysted sporozoites (Forney et 
a!. , 1996b). Additionally, we have demonstrated a significant 
anticryptosporidial potential for selected protease inhibitors, including 
human AAT, in a bovine fallopian tube epithelial (BFTE) cell culture system 
(Forney et a!., 1996a). Collectively, emerging evidence suggests that 
cryptosporidial protease/ peptidase activity is requisite for C. parvum 
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excystation and the initial dynamics of host cell infection. Speculation on the 
role of endogenous proteolytic enzymes during excystation prompted the 
present study to evaluate C. parvum for protease activity associated with peak 
periods of oocyst excystation. Further, our objectives included a study of the 
effects of selected inhibitors on parasite protease activity and oocyst 
excystation. 
MATERIALS AND METHODS 
Parasite propagation and isolation 
Oocysts were maintained by passage in experimentally infected 
Holstein calves, purified from feces using discontinuous sucrose and 
isopycnic Percoll gradients (Arrowood and Sterling, 1987), and stored in 2.5% 
potassium dichromate (K2Cr207) at 4°C. Oocysts were decontaminated in 
10% (v /v) bleach for 10 min at 4°C and washed thoroughly with sterile 
Hanks' balanced salt solution (HBSS) to remove residual bleach and K2Cr207. 
Decontaminated oocysts were harvested following centrifugal concentration 
and resuspended in sterile RPMI medium (HyClone Laboratories, Inc., Logan, 
Utah). 
Excystation studies 
Aliquots of purified oocysts were added to sterile plastic 
microcentrifuge tubes and intact oocysts were counted in a hemacytometer 
using phase contrast microscopy. Oocysts were then incubated at 37°C in the 
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absence of any further treatment (Bonnin eta!. , 1991; Robertson eta!., 1993; 
Upton et a!., 1994). Tubes were removed from the incubation environment at 
fixed time intervals, i.e., 15, 30, 60, 90, 120, and 180 min, and intact oocysts 
were again enumerated (excluding empty oocyst "ghosts" and partially-
excysted oocysts) . The difference between the number of oocysts counted 
prior to incubation and the number of oocysts counted after incubation was 
expressed as a percent of the original, i.e., pre-incubation, number. This value 
was termed "percent of excystation" and represented an indirect assessment of 
excystation. 
Preparation of parasite homogenate 
Bleach-treated oocysts were incubated at the timed intervals indicated 
previously and then snap frozen in liquid nitrogen to suspend further 
excystation. These partially excysted mixtures of oocyst and sporozoite forms 
were thawed in a 37°C water-bath and sonicated 6 X 45 seconds (50 mW) on 
ice to produce a C. parv um homogenate (CPH). Samples of the resulting 
sonicate were examined by light microscopy to ensure that CPH was free of 
intact oocysts and sporozoites. Peak protease activity was observed in 
homogenates prepared from oocyst incubated for 60 min; for subsequent 
inhibitor sensitivity studies, a 3-ml suspension of 106 oocysts/ml in RPMI 
medium was incubated at 37°C for 60 min and sonicated as before. CPH 
prepared in this fashion was assayed for total protein concentration 
(Bicinchoninic Acid Protein Assay, Pierce Scientific, Rockford, Illinois) and 
the final total protein concentration was adjusted to 200-250 !!g/ ml. 
Assay for proteolytic activity 
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Azocasein (Sigma Chemical Company, St. Louis, Missouri) was used as 
a substrate in a microassay protocol for proteolytic activity (Plantner, 1991). In 
brief, 200 111 aliquots of a 2 mg/ml solution of azocasein in 100 mM sodium 
phosphate buffer, pH 7.0, was prewarmed 15 min at 37°C. Evaluation of 
protease activity was confined to pH 7.0, consistent with the neutral 
excystation environment used in this study. A 50-!!1 aliquot of CPH was 
added to each tube and the reaction mixture was incubated at 37°C for 10 hr. 
Following incubation, 40-!!1 of 50% cold trichloroacetic acid (TCA) was added 
to each tube to precipitate undigested azocasein and tubes were placed on ice 
for 60 min. The reaction solution was clarified by centrifugation (7,000 g for 
10 min). A 200-!!1 aliquot of the reaction supernatant was added to individual 
wells in a 96-well microtiter plate; each well contained 20 111 of 10 N NaOH. 
The absorbance of the alkalinized solution was read at 450 nm (A4so) in an 
automated microtiter plate reader (Microplate Autoreader, Bio-Tek 
Instruments, Inc., Winooski, Vermont). Diluted commercial trypsin (Type 
IV; Sigma) was used as a control for casein hydrolysis. 
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Protease inhibitors 
The protease inhibitors alpha-1-antitrypsin (AAT; Chemicon 
International, Inc., Temecula, California), aprotinin (ICN Biochemicals, Inc., 
Aurora, Ohio), L-trans-epoxysuccinyl-leucylamindo-(4-guanidino)-butane (E-
64; Sigma), diisopropyl fluorophosphate (DIFP; Sigma), and 
phenylmethylsu!fonyl fluoride (PMSF; Sigma) were evaluated for their effect 
on CPH-associated protease activity and oocyst excystation. Dilutions of AAT 
and aprotinin were prepared in 10-Jlg/ ml and 100-Jlg/ml concentrations in 
sterile 25 mM phosphate-buffered saline (PBS); DIFP, E-64, and PMSF were 
first dissolved in dimethyl sulfoxide (DMSO; Sigma) and subsequently diluted 
to 1-mM and 10-mM concentrations in PBS. Inhibition studies involved the 
pre-incubation of equal volumes of CPH and protease inhibitors for 30 min at 
25°C prior to assay with azocasein. The differences in A450 values for 
inhibitor-treated CPH samples and untreated control samples (similarly 
diluted) were compared for statistical significance using ANOV A (Fisher's 
PLSD). 
To evaluate the effect of protease inhibitors on excystation, purified 
oocysts were mixed with equal volumes of protease inhibitor solutions and 
subjected to the excystation conditions previously described. The number of 
oocysts that excysted in inhibitor-treated groups was expressed as a percent of 
the number of oocysts excysted in untreated control samples. Inhibitors 
requiring preparatory dissolution in DMSO were matched with excystation 




Under standard conditions (37°C, RPMI medium) excystation increased 
rapidly during the initial 90 min (Fig. 3-1). The percent of excystation at 120 
(74.5 ± 1.41) and 180 (76.7 ± 2.12) min was increased over shorter incubation 
times, but did not significantly differ from the percent of excystation at 90 min 
(68.5 ± 1.06). In effect, 89.3% of the total excystation observed occurred within 
the first 90 minutes of incubation, with 78.2% occurring within the first 60 
min . 
Table 3-1 shows the effects of selected protease inhibitors on the 
excystation dynamics of C. parvum oocysts. The serine protease inhibitors 
PMSF, DIFP, aprotinin, and AAT significantly inhibited excystation (P < 0.05) 
in the sampling intervals from 15 to 60 min, but the percent of excystation 
obtained at 90-180 min was not significantly reduced below control levels by 
any of the protease inhibitors we evaluated. PMSF, at a concentration of 10 
mM, was the most potent excystation inhibitor evaluated. The cysteine 
protease inhibitor E-64 had no significant inhibitory effect on excystation. 
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Protease activity 
Protease activity was detected in CPH prepared from oocysts incubated 
at 37°C. Figure 3-1 shows the relationship between azocasein hydrolysis 
(A4so) and the length of time oocysts were incubated prior to 
homogenization. Protease activity was absent in unincubated oocysts; 
azocasein hydrolysis increased with oocyst incubation time, and peak activity 
was measured in CPH prepared from oocysts that were incubated for 60 min. 
Azocasein hydrolysis progressively declined in CPH prepared from oocysts 
incubated for 90- to 180-min intervals. 
Inhibitor sensitivity studies were conducted on CPH prepared from 
oocysts that had been incubated for 60 min to coincide with the period of 
highest hydrolytic activity. Cryptosporidial protease activity was significantly 
inhibited (P < 0.05) by the serine protease inhibitors PMSF, DIFP, and AAT at 
each of the concentrations evaluated (Table 3-2). Aprotinin significantly 
inhibited azocasein hydrolysis (P < 0.05) when tested at a concentration of 100 
Jlg/ml; a 10-Jlg/ml concentration of aprotinin had no significant effect on 
protease activity. The cysteine protease inhibitor E-64 significantly inhibited 
(P < 0.05) azocasein hydrolysis at concentrations of both 1 mM and 10 mM. 
The combination of 10 mM PMSF and 10 mM E-64 inhibited 95.8% of the 
hydrolytic activity measured in unchallenged control samples. 
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DISCUSSION 
This study reports the detection of proteolytic activity in homogenates 
prepared from C. parvum oocysts collected during peak periods of excystation. 
CPH-associated protease activity paralleled the increase in excystation 
observed with incubation of oocysts at 37°C (Fig. 3-1). Our findings showed 
that protease activity peaked at the 60-min incubation interval and steadily 
declined when oocysts were incubated for longer periods. Further, this study 
suggests that CPH contained proteases sensitive to both serine and cysteine 
protease inhibitors. 
The pattern of oocyst excystation observed in this study is consistent 
with previous reports of excystation dynamics. Upton eta!. (1994) reported a 
high rate of excystation during the initial 90 min of incubation at 37°C in 
RPMI medium. Whereas our study did not attain as high a percent of 
excystation as reported by those authors, the rapid rate of excystation we 
observed in the 15- to 90-min intervals is in substantial agreement. 
Robertson eta!. (1993) recommended a protocol for in vitro excystation that 
limited oocyst incubation to 30 min at 37°C to maximize sporozoite viability. 
In vitro studies strongly suggest that sporozoite viability, and subsequent 
infectivity, is optimally associated with the peak excystation period occurring 
during the initial 30-90 min of incubation at 37°C. 
As seen in Table 3-1, the pattern of excystation inhibition (inhibition by 
PMSF, DIFP, aprotinin, and AAT; lack of inhibition by E-64) strongly suggests 
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that a C. parvum serine protease(s) is functionally associated with excystation. 
Michalski et al. (1994) reported similar findings in a homogenate prepared 
from sporulated Eimeria tenella oocysts. Their study detected a mixed 
inhibitor sensitivity pattern indicative of the presence of both serine and 
cysteine proteases in E. tenella oocysts. 
The findings of this study suggest that C. parvum oocysts may also 
contain multiple proteases with inhibitor sensitivities characteristic of both 
the serine and cysteine protease classes. Nesterenko et al. (1995) reported a 
cysteine protease detected in solubilized sporozoite membranes. Because the 
homogenate used in the present study contained components of both oocysts 
and sporozoites, the E-64-sensitive component of CPH may represent the 
cysteine protease previously described. The potential expression of multiple 
proteases in a crude homogenate of C. parvum is certainly not an unexpected 
finding in protozoans. Multiple proteases have been reported in a number of 
parasitic genera, including Entameoba , Plasmodium , Trichomonas, 
Trypanasoma , and Leishmania (McKerrow et al. , 1993) Alternately, there is 
evidence of a malarial protease that exhibits an inhibitor sensitivity pattern 
suggesting serine and cysteine protease properties in a single enzyme 
(Deguercy et al., 1990). 
Our previous study reported an interaction between human AAT and 
C. parvum (Forney, 1996b). The localization of AAT complexes on the 
external surface of excysted sporozoites suggested the expression of a protease-
like component on this early developmental stage of the parasite. The 
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present study supports this hypothesis by demonstrating proteolytic activity 
and showing the antagonistic properties of serine protease inhibitors on 
excystation. The mechanism by which serine protease inhibitors block 
excystation is not fully understood. It has been shown that bleach treatment 
increases the permeability of the oocyst wall and enhances excystation 
(Reduker and Speer, 1985; Robertson et al., 1993). Our use of bleach to 
decontaminate oocysts may have provided a means for inhibitors to penetrate 
the oocyst wall and inhibit intra-oocyst proteases. We have not evaluated the 
effect of serine protease inhibitors on excystation of unbleached oocysts. 
The observation that inhibitor-treated oocysts eventually approached 
control levels of excystation after 90-180 min incubation suggests that 
excystation is only partially blocked by the inhibitors and concentrations 
evaluated in this study. The half-life of some inhibitors, such as PMSF and 
DIFP, is relatively short and loss of inhibitory effect may be attributable to the 
short half-life of these compounds. An alternative postulate is the potential 
for compensatory mechanisms in the parasite life-cycle that may facilitate 
excystation in an inhibitory environment. For example, it has been shown 
that cysteine proteases can proteolytically degrade the AAT molecule and 
effectively eliminate its inhibitory potential for serine proteases (Johnson et 
al., 1986; Potempa et al., 1986; Wright and Scarsdale, 1995). The presumptive 
indication of cysteine protease activity in CPH suggests a mechanism to 
potentially mediate the inhibitory effects of AAT on oocyst excystation. 
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In summary, the findings of this study suggest that multiple proteolytic 
components, one sensitive to serine protease inhibitors and the other to the 
cysteine protease inhibitor E-64, are expressed by C. parvum during 
excystation. These findings further suggest that cryptosporidial serine 
proteases are functionally associated with excystation. It is of particular 
interest to note that PMSF, AAT, and aprotinin, in addition to inhibiting 
excystation, have previously been shown to significantly reduce C. parvum 
infection in a permissive BFTE cell culture system (Forney et al., 1996a; Yang 
et al., 1996). Thus, protease inhibitors may reduce parasite infectivity in vitro 
by antagonizing excystation. Altering the dynamics of excystation may 
potentiate an effective anticryptosporidial strategy. 
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Table 3-1. Effect of protease inhibitors on excystation of Cryptosporidium parvum oocysts. 
% Inhibition . 
Protease Inhibitor Concentration 1st 30 60 90 
phenylmethylsulfonyl fluoride (PMSF) 10 mM 87.9f± 12.6 78.9f ± 9.1 56.1f± 5.8 11.3 ± 1.6 
diisopropyl fluorophosphate (DIFP) lOmM 66.7f ± 10.8 64.6+ ± 11.6 42.5+ ± 5.9 1.9 ± 1.5 
aprotinin 100 11g/ml 48.5f± 12.7 50.9f± 8.3 25.2:t:± 4.7 4.7 ± 1.6 
alpha-1-antitrypsin (AA T) 100 11g/ml 82.8f± 11.8 65.4:t:± 4.1 36.1+± 5.9 16.4 ± 1.5 
L-trans-epoxysuccinyl-leucylamindo-
(4-guanidino)-butane (E-64) 10mM 14.9 ± 8.1 12.7 ± 6.4 7.9 ± 1.2 -1.6± 1.1 
*Percent of control excystation inhibited by protease inhibitor treatment as described in Materials and 
Methods. Data derived from duplicate samples from 3 separate experiments. Values represent mean ± SO. 
+Time (min) of incubation at 37°C. 
+Significantly different (P < 0.05) from control group. 
Table 3-2. Effect of selected inhibitors on excystation-associa ted protease 
activity. 
Protease Inhibitor Concentration % Inhibition . 
PMSF 10mM 88.4± 4.2t 
1mM 67.0 ± 6.6t 
DIFP 10mM 80.8 ± 5.8t 
1mM 72.6± 4.1t 
Aprotinin 100 ~g/ml 65.7± 4.9t 
10 ~g/ml 9.8 ± 2.6 
AAT 100 ~g/ml 60.7± 4.4t 
10 ~g/ml 30.8± 2.3:j: 
E-64 10mM 37.7± 8.8t 
1mM 22.6± 3.5:j: 
PMSF + E-64 10 mM (each) 95.8 ± 6.7t 
88 
*Percent of protease activity in CPH controls inhibited following treatment 
with protease inhibitors as described in Materials and Methods. Data derived 
from duplicate samples from 3 separate experiments. Values represent 
mean± SD. 
tsignificantly different (P < 0.01) from untreated control group. 
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Figure 3-1. Effect of oocyst incubation time at 37°C on excystation and 
protease activity. Percent excystation (primary Y-axis) observed at fixed 












hydrolysis in C. parvum homogenates (CPH) prepared from oocysts incubated 
for designated intervals (--• --). Data points represent the mean value of 




ANTAGONISTIC EFFECT OF HUMAN ALPHA-1-ANTITRYPSIN ON 
EXCYSTATION OF CRYPTOSPORIDIUM PARVUM OOCYSTS1 
ABSTRACT: This study evaluated the effects of the human serine 
protease inhibitor alpha-1-antitrypsin (AAT) on in vitro excystation and 
infectivity of Cryptosporidium parvum. Oocysts used in excystation studies 
were subjected to bleach treatment, either directly from potassium 
dichromate storage or following cesium chloride (CsCl) purification. 
Unbleached CsCl-p.urified oocysts were used in control samples. Excystation 
was monitored at 37°C in RPMI medium in the presence of 0, 100, 500, or 1000 
Jlg / ml AAT. Samples were collected at timed intervals and the mean percent 
of excystation in AAT-treatment groups was compared to untreated control 
sample means. AAT significantly inhibited (P<0.05) excystation in a 
concentration-dependent manner at incubation intervals from 15-90 min. 
AAT did not significantly alter the excystation dynamics of unbleached 
oocysts. The effects of AAT were further evaluated in cultured bovine 
fallopian tube epithelial (BFTE) cells. Bleached oocysts, suspended in RPMI 
medium containing 0, 1, 10, 100, 500, or 1000 Jlg / ml AAT, were used to 
inoculate confluent BFTE cell monolayers. Inoculated cells were maintained 
at 37°C until collected at 24, 48, 72, or 96 hr post-inoculation. Alternately, 
'Coauthored by J. R. Forney, J. R. , S. Yang, and M. C. Healey. 1997. Journal of Parasitology 83: 
(in press). 
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sporozoites, excysted at 37°C and collected by filtration, were used to inoculate 
BFTE cells under the same conditions. The mean number of parasites 
counted in AAT-treated, oocyst-inoculated cells was significantly less (P<0.01) 
than control mean values at 24 and 48 hr post-inoculation; longer post-
inoculation intervals (72-96 hr) exhibited a decreased inhibitory effect. AA T 
did not significantly inhibit parasite infection when cultures were inoculated 
with C. parvum sporozoites. These data suggest that the anticryptosporidial 
potential of AAT is primarily associated with an antagonistic effect on oocyst 
excystation. 
INTRODUCTION 
Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is an 
enteropathogenic parasite that causes a diarrheal illness in humans. This 
protozoan preferentially invades the apical surface of epithelial cells lining 
the small intestine and exhibits the potential to colonize the intestinal and 
respiratory epithelia of immunocompromised hosts (Current et a!., 1983; 
O'Donoghue, 1995). The severity of human cryptosporidiosis is appreciable in 
the AIDS patient population and infection is frequently accompanied by 
chronic, protracted diarrhea (Petersen, 1992; Goodgame eta!., 1993, 1995). A 
number of potential anticryptosporidial compounds have been evaluated, yet 
there remains no definitive treatment for cryptosporidiosis that eradicates the 
parasite or reduces the chronicity of infection in susceptible hosts. 
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Alpha-1-antitrypsin (AAT) is a single chain glycoprotein composed of 
394 amino acid residues with a molecular weight of approximately 56 kDa 
(Travis and Salvesen, 1983). AAT is found in peripheral circulation and 
provides homeostatic regulation of proteolytic activity from endogenous 
proteases (Baumstark, 1967; Perlmutter, 1993). In humans, AAT helps 
mediate the systemic effects of inflammation and is particularly effective in 
inhibiting its cognate target enzyme, neutrophil elastase. At present, 
pharmaceutical preparations of AAT are therapeutically indicated to 
supplement inadequate AAT levels in patients with congenital deficiencies; 
its use as a potential anticoccidian reflects a novel application of the 
compound. 
Previous investigators have proposed the induction of parasite-derived 
mechanisms within the oocyst as the probable biochemical initiators of C. 
parvum excystation (Fayer and Leek, 1984; Reduker and Speer, 1985; Reduker 
et al., 1985; Woodmansee, 1987). Enzyme activity, specifically endogenous 
proteolysis, has been shown to facilitate excystation in the protists Giardia 
muris and Eimeria tenella (Feeley et al., 1991; North, 1992; McKerrow et al., 
1993; Michalski et al., 1994). Cryptosporidial oocyst can be induced to excyst by 
incubating at elevated temperatures and, although the level of excystation is 
quite low, water or buffered saline can serve as an excystation medium at 37°C 
(Fayer and Leek, 1984; Current, 1990). Exposing oocysts to protocols that 
putatively enhanced the permeability of the oocyst wall significantly increases 
the rate of excystation at 37°C. Accordingly, bleach treatment, acidification, 
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deoxycholic acid, taurocholic acid, and trypsin have been reported to optimize 
excystation and subsequent in vitro infection (Reduker et a!., 1985; Robertson 
eta!., 1993; Upton eta!., 1994). 
Although a role for proteolytic activity in excystation has been 
postulated for several years, only recently has proteolytic enzyme activity 
been reported in C. parvum. Okhuysen et a!. (1994) reported arginyl 
aminopeptidase activity in excysted C. parvum sporozoites and suggested a 
putative role for aminopeptidase activity in excystation. A subsequent report 
by Nesterenko et a!. (1995) demonstrated cysteine protease activity in 
solubilized membrane fractions of excysted sporozoites. Our previous studies 
have detected proteolytic activity (azocasein hydrolysis) in a parasite 
homogenate prepared from oocysts and sporozoites during peak periods of 
excystation (Forney eta!., 1996a). Further, we have reported an interaction 
between AAT and C. parvum that suggests the formation of serpin:enzyme 
complexes immunolocalized on the surface of freshly excysted sporozoites 
(Forney eta!., 1996b). 
In the present study we have pursued a thorough evaluation of the 
antagonistic effect of human AAT on the excystation of C. parvum oocysts. In 
particular, experiments were designed to investigate oocyst wall permeability, 
enhanced by bleach treatment, as a factor in AAT-mediated inhibition of 
excystation. We further evaluated the anticryptosporidial activity of AAT on 
both oocyst- and sporozoite-inoculated cultures and monitored serpin effects 
on in vitro infectivity over extended post-inoculation incubation intervals. 
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MATERIALS AND METHODS 
Parasite isolation and preparation 
Oocysts (Iowa strain) used in this study were propagated in 
experimentally infected Holstein calves, isolated from feces using sucrose and 
isopycnic Percoll gradients (Arrowood and Sterling, 1987), and stored in 
potassium dichromate (K2Cr20 7) at 4°C. In preparation for analysis, oocysts 
were packed by centrifugation and the bulk of the K2Cr20 7 was removed. The 
oocyst pellet was decontaminated in a 20% bleach (v / v) solution (Chlorox®, 
5.25 %sodium hypochlorite in stock concentration) for 10 min at 4°C and 
washed thoroughly with sterile Hanks' balanced buffered saline (HBSS, 
HyClone Laboratories, Logan, Utah) to remove residual bleach and K,Cr20 7• 
Oocysts were harvested by centrifugation and resuspended in sterile RPMI 
medium (HyClone). Alternately, the oocyst pellet was purified by CsCl 
flotation (ref) and used either directly following CsCl-purification or treated 
with bleach as previously described. CsCl-purified oocysts were washed in 
HBSS and resuspended in RPMI medium. 
Bleached-decontaminated oocysts, prepared directly from K,Cr20 7 
storage, were used in BFTE cell infectivity studies. Sporozoites for cell culture 
inoculation were prepared from bleach-decontaminated oocysts suspended in 
RPMI medium at a concentration of 1 X 107 oocysts/ml. The oocyst 
suspension was aspirated into sterile, prewarmed syringes, and incubated at 
37•c for 1 hr. The resulting mixture of oocysts and sporozoites was passed 
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through a sterile 5-J,J.m filter (Millipore Corporation, Bedford, Massachusetts) 
under gentle pressure and resuspended in RPMI medium to a final 
concentration of 2 X 106 / ml sporozoites. Samples of the filtered sporozoite 
inoculum were examined by brightfield microscopy and found to be negative 
for intact oocysts. 
Excystation studies 
AAT (Chemicon International, Temecula, California) was initially 
reconstituted as a 2000-J,J.g / ml stock solution in sterile RPMI medium and 
further diluted in lli'MI medium as needed. Oocyst samples (i.e., bleach-
treated before or after CsCl-purification) were mixed with AAT at 
concentrations of 100, 500, and 1000 J,J.g / ml. Intact oocysts were counted in 
each sample using a hemocytometer and phase contrast microscopy to 
establish a baseline oocyst number prior to incubation. Oocysts were then 
incubated at 37°C, removed from the incubator at fixed time intervals (15, 30, 
60, 90, 120, and 180 min), placed on ice to suppress further excystation, and 
intact oocysts were again counted. Unbleached, CsCl-purified oocysts were 
evaluated as control samples, both with and without AAT in the excystation 
medium. Because of the low rate of excystation observed for unbleached 
oocysts, incubation intervals were extended to 1-hr increments for a total of 6 
hr when assessing AAT effects. Empty "ghost" oocysts and partially excysted 
oocysts were not included in the enumeration process. The difference in the 
number of oocysts counted before and after incubation was expressed as a 
percent of the original, pre-incubation number. This value was termed the 
"percent of excystation" and used for comparative analysis of excystation 
between treated and control samples. 
In vitro infectivity 
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Infectivity studies involved the inoculation of BFTE cells with 105 
bleach-decontaminated oocysts/ml in RPMI medium containing AAT at 
concentrations of 1, 10, 100, 500, and 1000 ~g/ml. The stock serpin solution 
was passed through a 0.8-~m / 0.2-~m syringe filter (Acrodisc® PF, Gelman 
Sciences, Ann Arbor, Michigan) prior to use in cell culture and further 
diluted in RPM! medium as required. A 1.0-ml aliquot of the inhibitor:oocyst 
mixture was used to inoculate BFTE cell monolayers grown to confluence on 
glass coverslips placed in individual wells of a 24-well culture plate (Coming 
Glass Works, Corning, New York). Monolayers inoculated with C. parvum 
oocysts in the absence of serpin treatment served as an infection control 
group. Inoculated cells were maintained in a candlejar at 37°C for 24 hr 
(Luechtfeld et a!., 1982). After 24 hr incubation, the residual inoculum was 
rinsed off with sterile RPMI medium and cell monolayers were retreated with 
RPM! medium containing the same concentration of AAT as in the 
inoculum; coverslips representing the 24-hr post-inoculation treatment 
group were collected at this time. The remaining treatment groups were 
further incubated at 37°C/ 5% C02 and collected at 48-, 72-, and 96-hr post-
inoculation. A second experiment involved the addition of AAT to BFTE cell 
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monolayers that had been inoculated with 105 C. parvum oocysts and 
cultured for 24 hr prior to treatment. Coverslips were collected 24 hr after 
AAT treatment was applied to the established infections. A third treatment 
protocol involved the use of C. parvum sporozoites as a source of culture 
inoculum. Sporozoites were mixed with the same AAT levels noted 
previously to achieve a final concentration of sporozoites at 1 X 106 /mi. A 
1.0-ml aliquot of the AAT:sporozoite mixture was applied to BFTE cell 
monolayers and inoculated cells were maintained as described. Coverslips 
were collected at 24 and 48 hr post-inoculation. A final investigation 
paralleled the initial experiment, but was limited to a single AAT 
concentration (1000 f,!g/ml) in an oocyst inoculum. Treatment included the 
reapplication of AAT each 24-hr interval following the initial inoculation to 
evaluate the effect of daily retreatment; this manipulation helped ensure 
sufficient bioavailability of the serpin compound. Coverslips were collected 
at 24, 48, 72, and 96 hr post-inoculation. In all experiments, cell monolayers 
were removed at designated intervals, washed with RPMI medium, fixed in 
absolute methanol (10 min/25°C), rinsed with 25 mM PBS, and stained with 
Giemsa. Coverslips were mounted (inverted) on glass slides with a 
permanent mounting medium and examined by brightfield microscopy. 
Parasite enumeration 
Parasite enumeration in infected BFTE cells was performed by the 
method of Yang et al. (1996). In brief, parasites were counted in a single scan 
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(1,000X, oil immersion) across the diameter of a mounted coverslip (approx. 
65 high power fields). Intact oocysts observed in BFTE cell monolayers at the 
end of the designated post-inoculation periods were considered to be residual 
inoculum and were not counted. The mean number of parasites counted in 
each of the AAT treatment groups was expressed as a percent of the mean 
number of parasites counted in the infection control group. Differences in 
infection numbers were compared for statistical significance by simple 
ANOVA (Fisher's PLSD). 
RESULTS 
Excystation 
The observed excystation dynamic of bleach-treated oocysts was 
consistent with previous reports (Fayer and Leek, 1984; Woodmansee, 1987; 
Upton et al., 1994). The percent of excystation increased rapidly during the 
initial 90 min of incubation at 37°C with a progressive decline in the rate of 
excystation after 180 min incubation (Fig. 4-1). Unbleached CsCl-purified 
oocysts excysted at low levels over extended incubation periods. These 
oocysts required 37°C incubation for 6 hr before reaching mean excystation 
levels of ~30%; comparable excystation yields were obtained within 30 min 
with bleach-treated samples. 
AAT significantly inhibited (P<O.OS) excystation of bleach-treated 
oocysts in a concentration dependent manner (Fig. 4-2). The observed 
antagonistic effect was particularly evident during the early incubation 
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intervals from 15-90 min, but decreased progressively with extended 
incubation times. Further, both the duration of excystation inhibition and 
the degree of recovery were influenced by serpin concentration. Variation in 
bleach treatment (i.e., bleached directly from K2Cr,07 storage or following 
CsCI-purification) had no significant effect on AAT-mediated inhibition. As 
shown in Figure 4-3, excystation of CsCI-purified oocysts was not significantly 
inhibited by 1000 11g/ ml AAT; similar results were obtained for lower 
concentrations of the serpin (data not shown). 
In vitro infectivity 
AAT, at concentrations <!10 llg / ml, significantly inhibited (P<0.01) 
parasite infection in the 24- and 48-hr post-inoculation groups in cells 
inoculated with bleach-treated oocysts (Table 4-1). The inhibitory effect of 
AAT exposure decreased with increased culture incubation intervals; 
significant inhibitory activity (P<0.01) was limited to serpin levels <!500 11g/ ml 
in the 72-hr post-inoculation group and <! 1000 11g/ ml at 96 hr after 
inoculation. BFTE cell monolayers with established C. parvum infection 
were refractory to AAT and no significant inhibition was observed at any of 
the time periods evaluated (Table 4-1). 
AAT had no significant inhibitory effect on parasite numbers when 
sporozoites were used to inoculate BFTE cell cultures (Fig. 4-4). Similarly, the 
reapplication of human serpin at 24-hr intervals for the duration of post-
inoculation incubation periods did not significantly enhance the inhibitory 
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effect of the compound on in vitro infection relative to a single reapplication 
of AAT (Fig. 4-5). 
The observed results led us to question whether AAT had an adverse 
effect on BFTE cells such that parasite numbers were reduced independent of 
any potential anticoccicial activity. To help clarify this issue, BFTE cell 
monolayers were incubated with each of the respective concentrations of 
AAT for 24 hr prior to inoculation. Cells were then rinsed 4 times with RPMI 
medium to remove residual serpin, inoculated with either bleach-treated 
oocysts or sporozoites, and reincubated at 37°C/5% CO, for 24 hr. Infection 
rates obtained following AAT preincubation were not statistically different 
from the mean number of parasites counted in control samples preincubated 
with RPMI medium in lieu of AAT (data not shown). No cytotoxic effects 
were observed in culture cells incubated for up to 96 hr with AAT at the 
concentrations noted. 
DISCUSSION 
The results of the present study provide substantial evidence to link 
the in vitro anticryptosporidial activity of AA T to an antagonistic effect on 
oocyst excystation. This association is apparent from the differential 
inhibitory capacity of AAT on oocyst-inoculated cell cultures and the absence 
of significant inhibition on established in vitro infections. The lack of 
anticryptosporidial efficacy in this later group suggests that AAT exerts 
minimal effect on the asexual propagation of intermediate stages (merogony). 
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Further, AAT did not demonstrate a significant inhibitory effect on BFTE cells 
inoculated with freshly excysted sporozoites, suggesting that serpin activity 
does not alter parasite attachment and invasion. Neither was the diminution 
of anticryptosporidial activity over extended post-inoculation intervals 
attributable to a lack of biological availability of the serpin compound; 
retreatment of infected BFTE cells at daily (24-hr) intervals did not preclude 
the loss of inhibitory efficacy. 
Our data indicated that while AAT reduced the rate of excystation for 
bleached-treated oocysts, the serpin did not inhibit the excystation of 
unbleached oocysts. These findings suggest that parasite excystation is 
dependent upon endogenous mechanisms that are protected from serpin 
activity by the oocy5t wall. It is further apparent that permeability of the 
oocyst wall is requisite for AAT interactions with oocysts and/or sporozoites 
sufficient to alter excystation prior to the emergence of viable sporozoites. 
The oocyst wall is an effective barrier to AAT as long as the integrity of the 
wall remains intact. 
Infection control samples (i.e. , lacking AAT treatment) inoculated with 
sporozoites had considerably lower infection rates and exhibited greater 
variability than observed in cells inoculated with oocysts. While microscopic 
examination of aliquots taken from sporozoite suspensions prior to 
inoculation did not reveal the presence of intact oocysts, oocysts were 
occasionally encountered on sporozoite-inoculated coverslips. Filtration 
methods to produce C. parvum sporozoites minimize handling and reduce 
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the time interval from excystation to culture inoculation, but do not 
completely eliminate the inadvertent inclusion of oocysts in the final 
inoculation. Some of the variation noted in AAT treatment of sporozoite-
inoculated cells may be influenced by serpin effects on spurious oocysts in 
filtered samples and may not be solely representative of AAT effects on the 
early stages of in vitro infection. These groups lacked the concentration- and 
time-dependent relationships between AAT treatment and parasite numbers 
observed in oocyst-inoculated cultures. 
The antagonistic effect of AA T on excystation appears to be a transient 
process; continued incubation produced excystation yields levels approaching 
approximately 65-90% of the control group mean values. Despite the relative 
increase in excystation with continued incubation, it is noteworthy that oocyst 
inoculum containing AAT had significantly lower infection levels in the 
early post-inoculation treatment groups. The viability of emerging 
sporozoites appears to be directly related to the time lapse between the 
induction of excystation-related activity and final escape from the oocyst wall. 
Specifically, the time lag between the initial activation of excystation and the 
availability of susceptible host cells is a critical factor in C. parvum infectivity. 
The viability of excysted sporozoites is significantly diminished by excessive 
handling or delays in inoculating cultures (Robertson et a!., 1993). Sporozoite 
viability is relatively intolerant of delayed emergence and a loss of infectivity 
is evident in AAT-treated oocysts. It is reasonable to speculate that a 
significant portion of the finite energy stores within the sporozoite may be 
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consumed in the excystation process; failure to find an obligatory host cell 
shortly after emergence is detrimental to parasite infectivity. A similar 
relationship between sporozoi te energy expenditure and diminished viability 
has been reported in the related coccidian Eimeria tene/la (Yashwant et a!., 
1993). 
The findings presented support previous asertions that parasite-
derived biochemical mechanisms induced by elevated temperature and, 
possibly, other conditions in the microenvironment of excysting oocysts 
trigger the activation and emergence of sporozoites (Fayer and Leek, 1984; 
Woodmansee, 1987). Of particular interest is the association between 
antagonized excystation during initial incubation intervals and a subsequent 
reduction in BFTE cell infection demonstrated in this study. The 
implications of these findings suggest that not only is excystation induced by 
an activation of enzymatic processes, but once activated, bioenergetic demand 
may be the most important limitation of sporozoite viability. 
On the basis of this study, we conclude that AAT antagonizes C. 
parvum excystation when it can gain entry into the oocyst; enhanced 
permeability of the oocyst wall is necessary for the serpin to inhibit 
excystation. Further, these data suggest that sporozoite activation within the 
intact oocyst wall includes, at least in part, the expression of proteolytic 
enzyme activity. It is the association of protease activity with excystation, and 
the functional specificity of the AAT molecule for the active site of serine 
proteases, that provides the most likely mechanism for serpin-mediated 
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inhibition. The delayed excystation dynamic attributed to AAT accounts for 
its anticryptosporidial activity against in vitro infection, putatively by altering 
endogenous proteolytic activity within the intra-oocyst milieu. 
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Table 4-1. In vitro anticryptosporidial activity of alpha-1-antitrypsin in BFTE cell culture. 
% Infection Control 
[AAT]' +24t 24 48 72 96 
0 100 100 100 100 100 
1 99.8± 8.91 66.4± 9.2ll 72.6± 7.32+ 87.4± 12.24 96.9 ± 11 .82 
10 97.5 ± 9.91 48.0± 4.24+ 56.1 ± 4.54+ 82.1 ± 11.15 96.2± 9.68 
100 95.2 ± 10.11 38.4± 6.47+ 44.4±14.41+ 74.9 ± 10.04 81.1 ± 12.17 
500 88.2± 12.37 17.2 ± 12.93+ 27.3± 9.68+ 46.3± 8.62+ 62.6 ± 11.21 
1000 82.5 ± 18.81 10.8 ± 5.76+ 18.7± 5.97+ 31.6± 9.15+ 43.1 ± 7.12+ 
• Concentration in Jlg / ml. 
touration of AAT exposure (hr). A positive(+) sign indicates treatment was delayed until 
after inoculation; all other groups were treated at the time of culture inoculation with C. 
parvum oocysts. 
+Significantly different from control group (.!:<0.01); data represent mean± SD for duplicate 
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Figure 4-1. Pattern of excystation fo r bleach-treated Cryptosporidium parvum 
oocysts. Excystation yield from oocysts harvested directly from K,Cr20 7 
storage (-o-) or following CsCl-purification (-e-) compared to unbleached 
CsCl-purified oocysts (-• -). Values represent mean± SO for 3 replicates from 
each of 3 separate experiments. 
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Figure 4-2. Antagonistic effect of alpha-1-antitrypsin on Cryptosporidium 
parvum excystation. CsCI-purified, bleach-treated oocysts incubated at 37°C in 
the presence of 100 (-•-), 500 (-e-), or 1000 (-o-) J.Lg / ml purified human 
AAT. Data for bleach decontaminated oocysts from K,Cr20 7 storage was 
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Figure 4-3. Effect of alpha-1-antitrypsin on excystation of unbleached 
Cryptosporidium parvum oocysts. CsCl-purified oocysts incubated at 37°C in 
RPMI containing 1000 !lg/ ml human AAT (-o-) relative to untreated control 
samples (-e-). Values represents mean percent excystation for each 
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Figure 4-4. Effect of alpha-1-antitrypsin on infection of cultured epithelial 
cells inoculated with Cryptosporidium parvum sporozoites . Filter-isolated 
sporozoites were cultured in RPM! medium containing AAT for 24-hr (-e -) 
or 48-hr (-o-) post-inoculation intervals. Values represents mean ± SO for 
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Figure 4-5. Effect of alpha-1-antitrypsin retreatment on parasite numbers in 
cultured epithelial cells inoculated with Cryptosporidium parvum oocysts. 
Data represents the mean number of parasites counted in BFTE cell 
monolayers, expressed as a percent of untreated control sample means, 
containing 1000 ~-tg/ml AAT and cultured for 24 (white bar) or 48 (black bar) 
hr post-inoculation. Values indicate mean± SO for duplicate samples from 2 
separate experiments. 
CHAPTERS 




This chapter comprises 3 separate manuscripts originally prepared in 
the abbreviated format of a Research Note consistent with the requirements 
of the publishing journal. Though prepared as individual manuscripts, these 
notes provide a composite evaluation of the anticryptosporidial potential of 
select protease inhibitors with a particular emphasis on AAT. The ultimate 
contribution of this dissertation may reside in the applicability of these 
studies to the needs of the medical community; the increasing incidence of 
cryptosporidiosis in immunodeficient and immunocompromised 
individuals has substantially increased the morbidity and mortality of HIV 
infection. Overwhelming bouts of diarrheal illness, in excess of 70 liters of 
watery diarrhea a day, severely degrade the quality of life for AIDS patients. 
The lack of a curative agent to combat chronic cryptosporidial infection is a 
very real problem and efforts to identify candidate compounds for therapeutic 
trial are a worthy endeavor. 
The reader should recognize the progressive evolution and refinement 
of the studies upon which this chapter is based. The initial evaluation of 
AA T as a potential anticryptosporidial compound revealed a potent effect for 
the inhibitor in concentrations 2': 100 !lg/ml. Subsequent studies showed that 
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the inhibitory potential of AAT was noted at much lower levels and peaked 
at 24- to 48-hr post-inoculation; we later noted that efficacy waned when post-
inoculation intervals were extended to 2': 72 hr. It became increasingly 
apparent that AAT, and possibly other compounds in the general class of 
serine protease inhibitors, were potent antagonists of excystation of C. 
parvum oocysts. As an antiexcystation agent, it is reasonable to suggest that 
the reduction in initial excystation rates observed in the presence of AAT 
contributed to the decreased infectivity pattern noted in cell cultures 
inoculated with C. parvum oocysts. 
The amplification cycle of type I meronts appears to be refractory to 
serpin activity and the observed loss of in vitro efficacy for AAT during 
mergony likely reflects the propagation of intermediate stages of C. parvum. 
This hypothesis is strongly supported by results indicating a decreased 
inhibitory potential for AAT during prolonged post-inoculation intervals and 
a lack of significant inhibition of established infections. Further, AAT had no 
significant inhibitory effect on infection when excystation was accomplished 
prior to inoculation; sporozoite inocula containing AAT produced in vitro 
infection rates statistically indistinguishable from untreated control groups. 
The potent inhibition of excystation and early infection by AAT, 
followed by a progressive loss of anticryptosporidial activity, led to the 
consideration of a multi-compound evaluation. A strategy was employed to 
exploit the anticryptosporidial characteristics of AAT in combination with a 
second anticryptosporidial agent that preferentially targeted developmental 
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intermediates of the parasite. The aminoglycoside paromomycin was selected 
as a second treatment compound and this combination (i .e., AAT and 
paromomycin) demonstrated a potent synergistic activity against C. parvum 
infection in vitro. Thus, a rational approach to multi-compound evaluation 
in an in vitro system proved to be a highly successful strategy in preventing 
cryptosporidial infection. 
The manuscripts presented in this chapter have been modified from 
their original style to conform to format consistency and facilitate the reader's 
review of their contents. The abstract prefacing each section has been 
summarized in this introduction and a single, comprehensive literature cited 
section completes the chapter. 
EFFICACY OF SERINE PROTEASE INHIBITORS AGAINST 
CRYPTOSPORIDIUM PARVUM' 
The dynamic of host cell infection by Cryptosporidium parvum 
(Apicomplexa: Cryptosporidiidae) and the parasite's enigmatic residence 
within an intramembranous vacuole are poorly characterized events in the 
life-cycle of this organism. Other apicomplexan species reportedly undergo a 
series of events during which the apical complex of the organism attaches, 
orients, and, ultimately, facilitates penetration of the host cell membrane to 
1Coauthored by J. R. Forney, J. R., 5. Yang, C. Du, and M. C. Healey. 1996. Journal of 
Parasitology 82: 638-640. 
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assess an intracellular location for growth and development (Aikawa et a!., 
1978). The biochemical properties of sporozoans appear to include 1 or more 
protease-mediated steps in the host cell adhesion and invasion process. 
Hadley et a!. (1983) demonstrated a protease-dependent mechanism involved 
in parasite attachment and penetration of erythrocytes by Plasmodium 
knowlesi merozoites. Their study reported a significant reduction in 
infectivity following the exposure of merozoites to selected protease 
inhibitors. Other investigators have reported analogous findings in 
Plasmodium falciparum (Dluzewski et a!., 1986), Eimeria tene/la (Fuller and 
McDougald, 1990), and Eimeria vermiformis (Adams and Bushell, 1988), in 
which protease inhibitors reduced the in vitro infection of permissive host 
cells. 
The present study evaluated the anticryptosporidial potential of the 
protease inhibitors alpha-1-antitrypsin (AAT), antipain, aprotinin, leupeptin, 
methoxysuccinyl-ala-ala-pro-valine chloromethylketone (MAAPVCK), 
soybean trypsin inhibitor (SBTI), and phenylmethylsulfonyl fluoride (PMSF) 
in a bovine fallopian tube epithelial (BFTE) cell culture system. Our previous 
study (Forney eta!., 1996b) detected a functional interaction between human 
AAT and C. parvum, primarily associated with the invasive form 
(sporozoite) of the parasite. The functional specificity of AAT for the active 
site of serine proteases influenced the selection of inhibitors used in the 
present study. Our objective here was to evaluate the efficacy of the selected 
protease inhibitors in reducing the in vitro infectivity of C. parvum. 
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The BFTE cell culture system used in this study supports the complete 
development, i.e., asexual and sexual reproductive cycles, of C. parvum (Yang 
et a!., 1996) and has been validated as an analytical tool for screening potential 
anticryptosporidial compounds in previous studies with Immuno-C™ 
(Healey eta!., 1996) and paromomycin (S. Yang, per. comm.). Protease 
inhibitors AAT (Chemicon International, Inc., Temecula, California) , 
antipain (ICN Biochemicals, Inc., Aurora, Ohio), aprotinin (ICN), leupeptin 
(Calbiochem-Novabiochem Corp ., La Jolle, California), and SBTI 
(Calbiochem) were initially prepared in stock solutions of 10, 20, 100, 200, and 
1000 J.Lg/ml in RPM! medium (Hyclone Laboratories, Logan, Utah). 
MAAPVCK (Sigma Chemical Co., St. Louis, Missouri) and PMSF (Sigma) 
were first dissolved in dimethyl sulfoxide (DMSO; Sigma) and subsequently 
diluted in RPM! medium to prepare the same concentrations (MAAPVCK) or 
2, 4, and 6 mM concentrations (PMSF). Oocysts used in this study were 
successively propagated in Holstein calves. Isolated oocysts (Arrowood and 
Sterling, 1987) were decontaminated in 10% bleach for 20 min at 4°C, washed 
thoroughly with sterile Hanks' balanced buffered saline (HBSS), and 
resuspended in sterile RPM! medium. Immediately prior to inoculation, 
purified C. parvum oocysts were added to the previously prepared protease 
inhibitor dilutions to obtain 105 oocysts / ml at the final inhibitor 
concentrations tested, i.e., 5, 10, 50, 100, and 500 J.Lg / ml or 1, 2, and 3 mM for 
PMSF. A 1.0-ml aliquot of the inhibitor:oocyst mixture was used to inoculate 
BFTE cell monolayers grown to confluence on glass coverslips placed in 
118 
individual wells of a 24-well culture plate. Each protease inhibitor 
concentration was tested in either 2 (antipain, leupeptin, SBTI, PMSF, 
MAAPVCK) or 4 (AAT, aprotinin) well replicates in duplicate experiments. 
At least 2 wells per plate were inoculated with C. parvum oocysts in the 
absence of inhibitor treatment and served as an infection control group. 
Inoculated cells were maintained in a candlejar environment at 37°C. 
Coverslips were removed at 24 hr postinoculation and washed with sterile 
RPM! medium. Cell monolayers were fixed 10 min in 100% methanol, rinsed 
twice with 0.025 M PBS, stained with Giemsa for 2 hr, and rinsed with 
distilled water. Coverslips were mounted (inverted) on glass slides with a 
permanent mounting medium and examined by brightfield microscopy (oil 
immersion, lOOOX). 
Parasite enumeration was accomplished as previously described (Yang 
et al., 1996). Oocysts observed in the BFTE cell monolayers at the end of the 
incubation period were considered to be residual inoculum and not included 
in the enumeration process. The mean number of parasites counted in each 
of the protease inhibitor treatment groups was expressed as a percentage of 
the mean number of parasites counted in the infection control group. The 
difference between mean values for treatment and control groups was 
compared for statistical significance by ANOVA (Fisher's PLSD) using a 
StatView® statistical analysis application. 
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BFTE cells were permissive to C. parvum infection. Typically, at 24 hr 
post-inoculation, the infection control group exhibited a predominance of the 
type I and II meront developmental stages with few, if any, residual oocysts 
remaining from the inoculum. Parasite numbers were significantly reduced 
(P < 0.01) following treatment with leupeptin and SBTI at concentrations of 10 
and 50 ~-tg/ml, respectively (Table 5-1). The protease inhibitors AAT, antipain, 
and aprotinin significantly reduced (P < 0.001) parasite numbers at 
concentrations as low as 5-10 ~-tg / ml. MAAPVCK did not significantly reduce 
C. parvum infection of BFTE cells at any of the concentrations tested. PMSF 
significantly reduced (P < 0.001) parasite numbers to 40% of control values at a 
concentration of 3 mM (Table 5-2) . 
AA T, antipain, and aprotinin were the most potent inhibitors of C. 
parvum infection in the BFTE cell culture system. When concentrations of 
these protease inhibitors were increased to 1,000 ~-tg / ml in the inoculum, 
parasite numbers were reduced to 1.76 ± 0.4% (AAT), 6.64 ± 1.44% (antipain), 
and 9.44 ± 1.81% (aprotinin) of the infection control mean (Fig. 5-1). During 
the microscopic enumeration of parasites in BFTE cell monolayers treated 
with these 3 protease inhibitors, intact (unexcysted) oocysts were frequently 
observed. This observation was predominantly associated with protease 
inhibitor concentrations exceeding 100 ~-tg/ml and was confined to these 3 
inhibitors. There was no evidence of cytotoxicity for BFTE cells at the 
protease inhibitor concentrations evaluated in this study. 
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Anticryptosporidial potential attributable to protease inhibition 
strongly suggests that the dynamic influencing initial host cell:parasite 
interaction is facilitated by parasite protease activity. The present study 
demonstrated a significant in vitro inhibition of C. parvum infection by AAT, 
antipain, and aprotinin and significant, but quantitatively less, inhibition by 
leupeptin, SBTI, and PMSF. These findings are generally consistent with 
studies on related coccidians (Hadley eta!., 1983; Adams and Bushell, 1988; 
Fuller and McDougald, 1990). PMSF was the most potent inhibitor of Eimeria 
spp when evaluated at a concentration of 5 mM. Conversely, Hadley et a!. 
(1983) reported no significant inhibitory effect by either PMSF or antipain on 
erythrocyte invasion by P. knowlesi merozoites. In the present study, a lack of 
significant inhibition by MAAPVCK, in light of the effects of AAT, antipain, 
and aprotinin, is a presumptive indication that protease-like activity 
expressed by C. parvum may more closely resemble a trypsin-like serine 
protease, in terms of inhibitor sensitivity, rather than an elastolytic enzyme 
(Stein and Trainor, 1986; Potempa eta!., 1994). 
The results of this study add to the growing body of literature 
addressing the essential metabolic and physiologic roles of proteases in 
parasitic infection (North, 1992; Roose and Van Noorden, 1995). Parasite 
protease activity has been associated with host cell attachment (Arroyo and 
Aldrete, 1989), degradation of host proteins for parasite nutrition (Chappell 
and Dresden, 1986), tissue migration and penetration (McKerrow eta!., 1990), 
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cytotoxic effects (Lushbaugh et al., 1981), and parasite maturation and 
development (Richer et al. , 1993). 
This study is the first to report a significant reduction in C. parvum 
infection of cultured cells in the presence of protease inhibitors. These 
findings support a hypothesis that protease activity, putatively a serine 
protease enzyme, is an important biochemical constituent of the early 
infection dynamics of C. parvum. A recent report of arginyl aminopeptidase 
activity associated with C. parvum (Okhuysen et al., 1994) assessed a potential 
role for aminopeptidase activity in the excystation of oocysts. Our 
observation of intact residual oocysts in cell monolayers treated with serine 
protease inhibitors strengthens the association between proteolytic activity 
and excystation. These findings further suggest that the anticryptosporidial 
potential of protease inhibitors may reduce host cell vulnerability to parasite 
protease activity and may be a prefatory indication of a chemotherapeutic 
strategy to abrogate cryptosporidial infection. 
ANTICRYPTOSPORIDIAL POTENTIAL OF ALPHA-I-
ANTITRYPSIN' 
Cryptosporidium parvum is an intracellular protozoan parasite that 
preferentially infects epithelial cells lining the microvilli of the small 
intestine. Human cryptosporidiosis is particularly severe in the 
'Coauthored by J. R. Forney, 5. Yang, and M. C. Healey. 1996. Journal of Eukaryotic 
Microbiology 43: 635. 
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immunocompromised host and is recognized as a significant cause of 
morbidity in the AIDS patient population. The present lack of efficacious 
therapy is an impetus for investigative efforts to identify potential 
anticryptosporidial agents. Alpha-1-antitrypsin (AAT) is the major serine 
protease inhibitor (serpin) in human circulation and has a substantial 
homeostatic role in regulating excess proteolytic activity. Previous studies 
have detected an interaction between human AAT and components of C. 
parvum sporozoites (Forney et a!., 1996b). To evaluate the functional 
significance of serpin interactions, we investigated the anticryptosporidial 
potential of purified human AAT on 2 aspects of the early infection dynamics 
C. parvum. In this present study, we report the effects of AAT on in vitro 
excystation and cryptosporidial infection in a bovine fallopian tube epithelial 
(BFTE) cell culture system. 
Oocysts (Iowa strain) were amplified in Holstein calves. Isolated 
oocysts (Arrowood and Sterling, 1987) were decontaminated in 10% bleach for 
10 min at 4°C, washed with sterile HBSS, and resuspended in sterile RPM! 
medium (HyClone Laboratories). Purified human AAT (Chemicon 
International, Inc.) was initially prepared in stock solutions of 20, 200, 1000, 
and 2000 Jlg/ml in RPM! medium. For excystation studies, oocysts were 
mixed with equal volumes of the appropriate AA T stock solutions to obtain 
final serpin concentrations of 10, 100, and 500 Jlg / ml. Intact oocysts were 
counted in a hemacytometer using phase contrast microscopy. Oocysts were 
then incubated at 37°C in the absence of any further treatment (Robertson et 
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a!., 1993; Upton eta!., 1994). Tubes were removed from the incubation 
environment at fixed time intervals, i.e., 15, 30, 60, 90, 120, and 180 min, and 
intact oocysts were again enumerated (excluding empty oocyst "ghosts" and 
partially excysted oocysts). The difference between the number of oocysts 
counted prior to incubation and the number of oocysts counted after 
incubation was expressed as a percent of the original (preincubation) number. 
This value was termed "percent excystation" and represented an indirect 
assessment of excystation. To evaluate serpin effects on infectivity, C. 
parvum oocysts were added to the previously prepared AAT stock solutions 
to obtain 105 oocysts / ml at inhibitor concentrations of 10, 100, 500, and 1000 
f.!.g/ml. A 1.0-ml aliquot of each AAT:oocyst mixture was used to inoculate 
separate BFTE cell monolayers grown to confluence on glass coverslips placed 
in individual wells of a 24-well culture plate. Inoculated cells were 
maintained in a candlejar environment at 37°C. Monolayers were removed 
at 24 hr post-inoculation, washed with RPMI medium, fixed with absolute 
methanol, and stained with Giemsa. Coverslips were mounted (inverted) on 
glass slides with a permanent mounting medium and examined by 
brightfield microscopy (oil immersion, 1000X). Parasite enumeration was 
accomplished as previously described (Yang eta!., 1996). Intact oocysts 
remaining after 24 hr incubation were considered residual inoculum and not 
included in the enumeration process. The mean number of parasites counted 
in each of the protease inhibitor treatment groups was expressed as a 
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percentage of the mean number of parasites counted in an infection control 
group . 
Excystation studies demonstrated that AAT significantly (P<0.05) 
inhibited oocyst excystation in concentrations<! 10 11g/ml (Table 5-3). The 
inhibitory effect was greatest in the early incubation intervals from 0-60 min. 
Excystation yields typically attained 70-75% of untreated control samples 
when incubation was continued to 180 min with all but the highest levels of 
AAT evaluated (Table 5-3) . The functional specificity of AAT for the active 
site of serine protease enzymes suggests that protease activity, putatively a 
serine protease, facilitates oocyst excystation. 
Infectivity of C. parvum oocysts in BFTE cells was significantly 
inhibited (P<0.01) at each of the AAT concentrations evaluated (Table 5-4). 
Inhibition of in vitro infection exceeded 50% at AAT levels as low as 10 
11g/ ml and reached 95.4% at a concentration of 1000 llg/ml. The frequent 
observation of intact (unexcysted) oocysts in BFTE monolayers inoculated 
with oocysts in the presence of high concentrations of AAT further suggests 
an association between serpin activity and impaired excystation. 
These data describe a potent in vitro anticryptosporidial potential for 
human AAT and, collectively, strengthen the association between early 
excystation intervals and subsequent in vitro infection of host cells 
(Robertson eta!., 1993; Upton eta!., 1994). The findings of this study add to 
emerging evidence suggesting a requisite role for proteolytic enzyme activity 
in the infectivity of C. parvum (Forney et a!., 1996c; Nesterenko et a!., 1995; 
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Okhuysen et al., 1994) and, further, suggest the potential use of serine protease 
inhibitors in a therapeutic strategy to combat cryptosporidiosis. 
SYNERGISTIC ANTICRYPTOSPORIDIAL POTENTIAL OF THE 
COMBINATION ALPHA-I-ANTITRYPSIN AND 
PAROMOMYCIN' 
Cryptosporidium parvum (Apicomplexa: Cryptosporidiidae) is an 
enteropathogenic protozoan that invades the intestinal epithelium in a 
number of mammalian species (O'Donoghue, 1995). Cryptosporidiosis is 
particularly severe in the immunocompromised human host and infection is 
frequen tly characterized by a profuse, watery (termed "cholera-like") diarrheal 
illness. Growing concern about the potential for human infection, 
particularly as acquired through municipal water supplies, and the sequela of 
chronic infection in susceptible hosts constitutes a significant emerging 
infectious disease threat (CDC, 1994; MacKenzie et al., 1994). The 
formidability of chronic infection is accentuated by the present lack of 
efficacious therapy. The search for anticryptosporidial agents has included the 
evaluation of numerous compounds in various in vitro and in vivo models, 
as well as in human clinical trials. This pursuit has been plagued by 
inconsistent therapeutic responses, recrudescence of infection following 
'Coauthored by J. R. Forney, S. Yang, and M. C. Healey. Antimicrobial Agents and 
Chemotherapy (submitted March 1997). 
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cessation of treatment, and the apparent autoinfective life-cycle of C. parvum 
in chronic infection states. 
Reports of proteolytic enzyme activity in the early developmental 
stages of C. parvum have prompted consideration of serine protease, cysteine 
protease, and arginyl aminopeptidase inhibitors for anticryptosporidial 
properties. Okhuysen et al. (1994) first reported cryptosporidial 
aminopeptidase activity and further demonstrated the ability of alpha-
aminoboronic acid derivatives to inhibit C. parvum peptidase activity and 
oocyst excystation (Okhuysen et al. , 1995). Other investigators have reported 
cysteine protease activity associated with C. parvum sporozoite membrane 
fractions (Nesterenko et al., 1995) and a reduction in parasite infectivity 
following exposure of sporozoites to the cysteine protease inhibitor L-trans-
epoxysuccinyl-leucylamindo-(4-guanidino)-butane (E-64) in MOCK cell 
culture (Huang and Petersen, 1996). Additionally, we have demonstrated a 
potent anticryptosporidial potential for select serine protease inhibitors, 
including human alpha-1-antitrypsin (AAT), in a bovine fallopian tube 
epithelial (BFTE) cell culture system (Forney et al., 1996b). These collective 
observations strongly suggest that protease/peptidase activity is requisite for 
the early infection dynamics of C. parvum and further suggest a potential 
chemotherapeutic role for protease inhibitors in controlling cryptosporidiosis. 
Marshall and Flanigan (1992) reported a significant reduction in C. 
parvum infection in a differentiated human enterocyte cell line, HT29.74, 
using the aminoglycoside paromomycin. Further studies have reported a 
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significant anticryptosporidial effect for paromomycin in immunosuppressed 
mice (Healey eta!. , 1995), immunosuppressed rats (Rehg, 1994; Verdon eta!., 
1994), calves (Fayer and Ellis, 1993b), SCID mice (Tzipori eta!., 1994), and in 
human clinical trials (Clezy eta!., 1991; Fichtenbaum eta!., 1993; Bissuel eta!., 
1994; Flanigan eta!., 1996). A report of paromomycin treatment followed by 
the administration of letrazuril noted an improved therapeutic response in 
treating AIDS-related cholangitis (Hamour eta!., 1993). Fayer and Ellis (1993a) 
evaluated the anticryptosporidial efficacy of select aminoglycosides, to include 
paromomycin, in single and combined therapy trials with tetracycline, in a 
neonatal mouse model. Their findings showed a significant reduction in 
cryptosporidial infection following administration of paromomycin, but did 
not reveal a synergistic effect in combination with tetracycline derivatives. 
In the present study we evaluated the combined effects of the serine 
protease inhibitor (serpin) AAT and paromomycin in BFTE cell culture. A 
putative role for serpin activity in antagonizing oocyst excystation (Forney et 
a!., 1996a) and the anticryptosporidial efficacy of paromomycin, particularly 
against intermediate stages of C. parvum, suggests that these compounds 
target different stages in the developmental life-cycle of the parasite. Our 
specific intent was to exploit the potential for enhanced efficacy from these 2 
compounds when used simultaneously in an in vitro assay. 
Oocysts used in this study were propagated in experimentally infected 
Holstein calves, isolated from feces using discontinuous sucrose gradients 
(Arrowood and Sterling, 1987), and stored in 2.5% potassium dichromate 
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(K2Cr20 7) at 4°C. Prior to cell culture inoculation, oocysts were 
decontaminated with a 10% (v /v) bleach solution for 10 min at 4°C and 
washed with HBSS to remove residual K2Cr20 7 and bleach. Bleach-
decontaminated oocysts were resuspended in RPMI.1640 base medium (RPMI; 
HyClone Laboratories, Logan, Utah) at a concentration of 2 X 105 oocysts/ml. 
Primary BFTE cell cultures were prepared by the method of Yang et al. 
(1996) and used to evaluate anticryptosporidial activity. In brief, epithelial 
cells were collected from the mucosal surface of bovine fallopian tubes (E. A. 
Miller & Sons Packing Company, Hyrum, Utah) by flushing the tubes 
multiple times with sterile HBSS. Cells were thoroughly washed in HBSS, 
packed by centrifugation (200 X g for 10 min), introduced into culture flasks 
containing RPMI supplemented with 10% fetal bovine serum (FBS; HyClone), 
and cultured at 37°C/5% C02. Cells were trypsinized and seeded onto glass 
coverslips in individual wells of 24-well culture plates (Coming Glass Works, 
Corning, New York) using unsupplemented RPMI. BFTE cells were 
maintained at 37°C/5% C02 until monolayers reached confluence. 
Stock solutions of human AA T (Chemicon International, Inc., 
Temucula, California) and paromomycin (Warner Lambert/Parke Davis, 
Ann Arbor, Michigan) were prepared in RPMI at concentrations of 1000 
IJ.g/ml (AAT) or 2400 IJ.g/ml (paromomycin) and passed through a 0.8-
IJ.m/0.2-j.lm syringe filter (Acrodisc® PF, Gelman Sciences, Ann Arbor, 
Michigan). Stock concentrations were further diluted in RPMI as needed. 
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To evaluate the differential efficacy of each compound, 
decontaminated C. parvum oocysts were added to RPM! containing AAT at 
concentrations of 1, 10, 100, and 500 l!g / ml or paromomycin at levels of 150, 
300, 600, and 1200 l!g / ml. A 1.0-ml aliquot of each of the resulting mixtures 
(105 oocysts) was used to inoculate BFTE cell monolayers. To evaluate the 
combined effects of AAT and paromomycin, each concentration of AAT was 
combined with each level of paromomycin for a total of 16 combined 
treatment groups. A mixture of C. parvum oocysts in RPM! alone was used 
to inoculate infection control samples. The same concentrations of 
compounds, single and combined, were added to BFTE cell monolayers to 
assess the effect of the compounds on BFTE cells. Inoculated cells were 
maintained in a candlejar environment at 37°C for the initial 24-hr post-
inoculation period. At 24 hr post-inoculation, cell monolayers were rinsed 
with RPMI to remove residual inoculum and either collected or retreated 
with the same concentration of compound(s) present in the initial inoculum 
and further incubated at 37°C / 5% C02. 
BFTE cell monolayers were collected at 24, 48, 72, and 96 hr post-
inoculation and fixed 10 min in absolute methanol at room temperature. 
Fixed cells were rinsed with 25-mM PBS, stained with Giemsa, and rinsed 
with distilled water. Coverslips were mounted (inverted) on glass slides with 
a permanent mounting medium and examined by brightfield microscopy (oil 
immersion, 1000X). Parasite enumeration was accomplished as described by 
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Yang et a!. (1996). In brief, parasites were counted in a single scan across the 
diameter of each coverslip (approx 65 high-power fields) and the mean 
number of parasites counted in each of the treatment groups was expressed as 
a percentage of the mean number of parasites counted in an infection control 
group . 
Synergistic potential was evaluated by calculating fractional inhibitory 
concentration (FIC) indices as described by Berenbaum (1978) and interpreted 
according to Allen eta!. (1982) . This method is based on the proportional 
relationship between IC50 values for single and combined treatment groups 
and was calculated in this study using the following formula: 
ICso of AA Tin combination ICso of paromomycin in combination 
FIC + 
ICso of AA T alone ICso of paromomycin alone 
FIC values were interpreted as follows: 
FIC < 0.5 = Significant synergism 
FIC 0.5 - 0.9 = Suggestive of synergism 
FIC 1.0 = Additive effect 
FIC 1.1- 1.9 Indifference or partial antagonism 
FIC ~ 2.0 Antagonism 
The difference between the mean number of parasites counted in 
treatment and control groups was compared for statistical significance by 
ANOVA (Fisher's PLSD) . Similarly, the mean number of parasites counted 
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in combined treatment groups was compared to both single compound 
treatment groups and corresponding infection control groups for statistically 
significant differences. The 50% inhibitory concentration (IC50) values for 
AAT and paromomycin treatment alone, and for combined treatment effects, 
were calculated using curve-fitting algorithms in the StatView™ data 
analysis program. 
The anticryptosporidial effect of AAT on in vitro oocyst infectivity was 
concentration dependent and exhibited an inhibitory pattern similar to that 
previously reported (Forney et al., 1996b). AAT significantly reduced (P <0.01) 
C. parvum infection in BFTE cells at concentrations<:: 1 11g/ ml at 24 hr post-
inoculation relative to untreated control samples. Serpin activity was 
progressively less inhibitory to C. parvum infection with increased post-
inoculation intervals;<:: 100 11g/ml was required to produce a significant 
inhibitory effect (P <0.01) at 96 hr post-inoculation (Fig. 5-2a). The pattern of 
decreasing efficacy is further evident in the IC50 values determined for AAT at 
each of the post-inoculation sampling periods (Table 5-S). 
Paromomycin significantly inhibited (P <0.01) in vitro cryptosporidial 
infection at concentrations ~ 150 11g/ml at each of the post-inoculation 
sampling intervals (Fig. 5-2b) . The inhibitory effect of paromomycin was 
concentration dependent and progressively increased with continued 
incubation of inoculated cultures. The most potent anticryptosporidial effect 
for paromomycin was observed in the 48- to 96-hr post-inoculation intervals 
and, at 1200 11g/ml, paromomycin consistently reduced parasite numbers 
>90% relative to infection control samples. As seen in Table 5-5, the IC50 
values determined for paromomycin decreased with extended post-
inoculation sampling intervals. 
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The combined application of AAT and paromomycin in an oocyst 
inoculum significantly inhibited (P <0.01) C. parvum infection at each of the 
combinations and post-inoculation sampling intervals monitored in this 
study (Fig. 5-3). The inhibitory effect of combined treatment was 
concentration-dependent at the 24- to 48-hr post-inoculation sampling 
intervals. The contributory effect of AAT concentration was Jess evident in 
the latter sampling periods, consistent with the diminished 
anticryptosporidial potency noted for the serpin in single compound 
treatment groups at 72 and 96 hr post-inoculation. 
FIC indices were calculated for combined treatment groups to evaluate 
the potential synergistic response of the 2 compounds relative to single 
treatment efficacy. The mean FIC value for combined treatment groups at 24-
hr post-inoculation was 0.1835 , indicating a significant synergistic interaction 
for the combination of AAT and paromomycin. Mean FIC values increased 
with longer incubation intervals, but continued to fall in a range indicative of 
synergistic activity despite the relative decrease in the anticryptosporidial 
contribution of AAT (Table 5-1). 
The present study is the first to demonstrate a synergistic 
anticryptosporidial effect for the combination of a serine protease inhibitor 
and an aminoglycoside. While both AA T and paromomycin have previously 
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been reported to reduce in vitro C. parvum infection, the findings presented 
here show an enhanced inhibitory effect was achieved when oocysts were 
simultaneously exposed to these 2 compounds at the time of inoculation. 
Further, these data illustrate the potential for a chemotherapeutic strategy to 
control cryptosporidiosis using multiple compounds targeting different 
developmental stages of the parasite. 
The results of this study are in substantial agreement with previous 
studies of the in vitro efficacy of AAT and paromomycin. Human AAT has 
been reported to reduce parasite infection in BFTE cells in a concentration and 
time-dependent manner (Forney et a!., 1996c). Similarly, a progressive 
decrease in the anticryptosporidial activity of AAT was observed with 
increased incubation periods. Further, AAT has been shown to exert an 
antagonistic effect on C. parvum excystation, putatively altering excystation 
dynamics with a subsequent decrease in sporozoite viability. 
Consistent with the findings of Marshall and Flanigan (1992), 
paromomycin demonstrated a significant inhibitory effect on C. parvum 
infection at 24 hr post-inoculation. The mode of action for paromomycin in 
reducing C. parvum infection is unknown. In general, aminoglycosides 
inhibit protein synthesis at the ribosome level and similar activity has been 
proposed for the inhibitory effect of paromomycin on in vitro Giardia Iamblia 
infection (Edlind, 1989). Rehg (1994) evaluated 6 different aminoglycoside 
compounds for anticryptosporidial activity in an immunosuppressed rat 
model and found that only paromomycin exhibited a significant inhibitory 
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effect on C. parvum infection. The observation that paromomycin is 
particularly effective against intermediate stages of C. parvum suggests that 
the compound may preferentially target protein synthesis associated with 
proliferative asexual development. 
The use of multi-compound protocols is a clinically relevant strategy 
for treating microbial infections. Combined drug therapy has the advantage 
of reducing toxicity by obtaining an effective response at lower concentrations 
and may delay the development of drug resistance. In the present study, the 
combination of 2 compounds putatively active against different 
developmental stages of C. parvum demonstrated the potential to exploit 
individual anticryptosporidial activities to facilitate an enhanced inhibitory 
response. 
In summary, we have demonstrated that AAT and paromomycin can 
be used in combination to significantly reduce in vitro cryptosporidial 
infection. Using the criteria of FIC indices, we have shown a synergistic effect 
for this multi-compound combination in BFTE cell culture. It is readily 
acknowledged that in vitro activity is not a universal indicator of analogous 
in vivo success and caution is warranted in the extrapolation of results based 
solely on in vitro assays. Further studies of the efficacy, toxicity, and systemic 
effects of multi-compound treatments in an appropriate experimental in vivo 
model are needed to better elucidate their potential therapeutic utility. The 
findings presented here demonstrate the capability to achieve a marked 
reduction in C. parvum infection and may constitute an alternative approach 
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to conventional single-agent treatment protocols. The present study supports 
the continued evaluation of multi-agent combinations for enhanced 
anticryptosporidial activity and suggests exciting possibilities for future 
investigative efforts. 
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Cryptosporidium parvum in bovine fallopian tube epithelial cells . 
Infection and Immunity 64: 349-354. 
Table 5-l. Effect of selected protease inhibitors on Cryptosporidium parvum infection of 
bovine fallopian tube epithelial cells. 
. 
%of Control 
[PI]t AAT Aprotinin Leu pep tin SBTI MAAPVCK Anti pain 
0 100 100 100 100 100 100 
5 49.1± 3.78§ 83.9± 6.56t 89.1± 5.41 100.3± 4.25 95.2± 3.68 67.74±7.15§ 
10 43.9±4.21§ 54.2±5.99§ 64.8±11.98t 95.9± 7.34 91.8± 5.23 53.11±5.78§ 
50 42.7± 1.62§ 36.1±4.72§ 58.7±11.21 t 70.2± 4.25t 79.2±13.65 42.13±6.14§ 
100 30.4± 1.8~ 16.8± 5.13§ 51.9± 4.64§ 68.3±11.59t 80.2±19.09 20.94±2.16§ 
500 14.7± 6.31§ 10.9±4.71§ 43.4± 6.5~ 50.5± 2.71§ 77.5± 9.69 15.58±1.44§ 
·Mean number of parasites counted per treatment group expressed as a percent± SO of the 
mean number of parasites counted in the infection control group; alpha-1-antitrypsin 
(AAT}, soybean trypsin inhibitor (SBTI), methoxysuccinyl-ala-ala-pro-valine 
chloromethylketone (MAAPVCK) . 
t [PI] = Protease inhibitor concentration (~tg/ml) in RPM! medium used in the BFTE cell 
inoculum. 
tsignificantly different from control group mean at P < 0.01. 
§Significantly different from control group mean at P < 0.001. 
Table 5-2. Effect of phenylmethylsulfonyl fluoride on Cryptosporidium 
parvum infection of bovine fallopian tube epithelial cells. 
[PMSF] % of Controlt 
OmM 100 
1mM 68.9± 5.23t 
2mM 55.9± 4.67t 
3mM 40.0± 8.34§ 
[PMSF] = Phenylmethylsulfonyl fluoride concentration (mM) in 
RPMl medium used in the BFTE cell inoculum. 
tMean number of parasites counted per treatment group expressed as a 
percent± SO of the mean number of parasites counted in the 
infection control group. 
+significantly different from control group mean at P < 0.01. 
§Significantly different from control group mean at P < 0.001. 
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Table 5-3. Effect of alpha-1-antitrypsin on Cryptosporidium parvum oocyst 
excystation at 37°C. 
% Excystation+ 
[AAT( 30 60 
0 16.5±2.4 27.5±4.1 54.5± 8.9 
10 5.2±1.1 t 18.5±4.4* 45.5±10.0 
100 3.2±1.8t 9.5±2.1t 39.7±11.8t 
500 1.8±0.7t 8.2±1.2t 19.8± 6.2t 
'concentration in ~-Lg/ml 
+Time (min) of incubation 







74.5± 9.8 77.1±10.6 
69.9±14.6 72.1±14.2 
64.5± 9.8t 69.6±12.7 
40.8±10.2t 52.5±13.2* 
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Table 5-4. Effect of alpha-1-antitrypsin on Cryptosporidium parvum infection 







·concentration in Jlg/ml 
tsignificant at (P<O.Ol), mean ± SO 
% of Infection Control Group 
100 
48.1 ± 6.8zt 
36.8 ± 3.s8t 
18.3 ± 7.18t 
4.6 ± 2.21t 
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Table 5-S. In vitro anticryptosporidial activity of alpha-1-antitrypsin and 
paromomycin in single and combined treatment groups 
Post-inoculation interval (hr) 
Treatment" 48 72 96 
AA Tt 10.2 ± 2.8 
Paromomycin* 262.7 ± 33.4 
AAT + Paromomycin§ 0.1835 
26.3 ± 9.8 
128.2 ± 9.1 
0.3781 
466.8±52.6 
80.6 ± 12.4 
0.7895 
494.6± 75.9 
73.4 ± 9.5 
0.8571 
"Treatment applied at the time of cell culture inoculation. 
tDenotes time (hr) post-inoculation. 
:!:values represent mean concentration (J.Lg / ml) ± SD (duplicate samples) 
capable of reducing parasite infection to 50% of mean control value (IC50). 
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Figure 5-1. Effect of protease inhibitors on infection of bovine fallopian tube 
epithelial cell monolayers by Cryptosporidium parvum oocysts. Data reflect 
the mean number of parasites counted at 24 hr postinoculation, expressed as a 
percent of the infection control mean, following treatment with alpha-1-
antitrypsin (-D-), antipain (-A-), and aprotinin (-e -). Error bars represent 1 
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Figure 5-2. Single compound treatment effect on Cryptosporidium parvum 
infection in BFTE cells using alpha-1-antitrypsin or paromomycin. Values 
represent infection mean± SD for duplicate samples in 2 separate 
experiments using (a) AAT or (b) paromomycin. Sampling intervals were 
conducted at 24 hr (-•-), 48 hr (-0-), 72 hr (-0 -), and 96 hr (-e-). 
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Fig. 5-3a Fig. 5-3b 
Fig. 5-3c Fig. 5-3d 
Figure 5-3. Effects of alpha-1-antitrypsin and paromomycin concentrations in 
combined treatment groups. Infection values for (a) 24, (b) 48, (c) 72, and (d) 
96 hr post-inoculation sampling intervals. Data reflects mean values for 
treatment groups expressed as a percent of untreated control samples 
(duplicate samples) from a typical experiment. Replicate experiments 
produced similar effects. 
CHAPTER 6 
SUMMARY AND CONCLUSIONS 
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The studies presented herein provide unequivocal evidence of the 
recognition and functional interaction of AAT with a component of C. 
parvum, putatively expressing serine protease-like activity during 
excystation. The biological significance of the observed serpin:parasite 
interaction is a potent antagonistic effect on oocyst excystation with a 
concomitant reduction in cryptosporidial infectivity in a permissive cell 
culture system. It is readily apparent from these studies that the alteration of 
the early infection dynamics of C. parvum, in particular the interval 
encompassing excystation and initial host cell attachment, has a substantial 
inhibitory effect on parasite infection. 
The antagonistic role of AAT in inhibiting excystation is attributed to 
the functional specificity of the serpin molecule for the active site of serine 
protease enzymes. Immunolocalization of SEC interactions on the 
membrane of excysted C. parvum sporozoites suggests the expression of a 
cognate target enzyme on this early developmental stage of the parasite. 
Further, the ability to block AAT recognition of C. parvum with porcine 
pancreatic elastase substantiates the specificity of the interaction and 
demonstrates a functional capacity for serpin activity in mediating the 
biological activity of the invasive sporozoite. 
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Select serine protease inhibitors (i.e., PMSF, SBTI, AA T, and aprotinin) 
and serine/cysteine inhibitors (i.e., leupeptin and antipain) showed potent 
anticryptosporidial potential in preventing infection in cultured epithelial 
cells. Further characterization of the anticryptosporidial activity of AAT 
showed a significant reduction in C. parvum infection in BFTE cells at 24-48 
hr post-inoculation, but the inhibitory effect of this serpin diminished with 
continue incubation intervals ranging from 72 to 96 hr post-inoculation. 
Similarly, AAT had very little effect on established in vitro infections, 
suggesting a minimal impact on developmental intermediates of the parasite. 
The differential antagonistic capability of AAT on oocyst excystation 
was restricted to oocysts that had been subjected to treatments known to 
increase the permeability of the oocyst wall (i .e., bleach decontamination, 
incubation in an acidic medium, exposure to deoxycholic acid); entry of AAT 
into the intraoocyst milieu required at least partial degradation of the oocyst 
wall. The excystation of CsCl-purified oocysts not otherwise subjected to any 
permeability-enhancing chemical pretreatments was not significantly 
inhibited by AAT. Rather than consigning the role of AAT in antagonizing 
excystation as "limited" in terms of its applicability to permeabilized oocysts, 
it is more accurate to view the association as physiologically relevant in light 
of the progressive passage of oocysts through the digestive system following 
ingestion. The biochemical analogy to gut passage and excystation in the 
lumen of the small intestine (i.e., acidification, neutralization, exposure to 
bile extracts and emulsifying agents) facilitates oocyst excystation and, 
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ultimately, enhances parasite vulnerability to serpin-mediated reduction in 
excystation efficiency. The effect of serine protease inhibitors on the 
excystation dynamics of thin-walled oocysts has yet to be evaluated; the 
assumed role of this type of oocyst in perpetuating chronic infection in 
susceptible hosts suggests a particularly interesting study for future 
consideration. 
A curious characteristic of AAT's antagonistic effect on excystation was 
the progressive loss of inhibitory potential with increased incubation 
intervals. The half-life of AAT in human circulation is in the range of 3-5 
days in the noninflammatory state; degradative capacity secondary to a 
reduced half-life does not seem to be a plausible explanation for the decreased 
inhibitory effect AAT had on excystation at 2- to 3-hr incubation intervals. 
One possible explanation for the time-dependent loss of efficacy is the 
consumptive nature of the serpin interaction. The serpin molecule binds 
covalently to a cognate target enzyme and remains bound, under physiologic 
conditions of the human system, until cleared from circulation. In effect, 
AA T is a "suicidal" inhibitor. Alternatively, C. parvum may possess 
mechanisms to counter serpin activity and, therefore, reduce the inhibitory 
capacity of the serpin. The reported ability of cysteine proteases to cleave the 
reactive site loop of the AA T molecule suggests a mechanism to rapidly 
degrade the molecule's ability to recognize and complex with proteases. This 
latter mechanism has been reported to enhance the pathogenicity of bacteria, 
and the putative identification of cysteine protease activity in C. parvum 
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suggests that studies evaluating degradation of AAT may be of interest in 
characterizing parasite defense mechanisms to acute phase proteins such as 
AAT. 
The transient nature of AAT effects on excystation was a consistent 
feature of the studies reported here; continued incubation of AAT-treated 
oocysts at 37°C typically produced excystation yields approaching 
approximately 65-80% of control group mean values. Despite the relative 
increase in excystation with continued incubation, it is noteworthy that oocyst 
inoculum containing AA T had significantly lower infection levels in the 
early post-inoculation treatment groups. The viability of emerging 
sporozoites appears to be directly related to the time interval between the 
induction of excystation-related activity and final escape from the oocyst wall. 
Specifically, the time lapse between the initial activation of excystation and 
the availability of susceptible host cells is a critical factor in C. parvum 
infectivity. Sporozoite viability appears to be relatively intolerant of delayed 
excystation and a significant loss in infectivity is evident in AAT-treated 
oocysts. It is likely that the invasion process (i.e., from excystation to 
formation of the parasitophorous vacuole) is dependent upon preexisting 
energy stores within the sporozoite; failure to find an obligatory host cell 
shortly after emergence is detrimental to infectivity. Though speculative at 
present, the implications of the results presented herein suggest that not only 
is excystation induced by an activation of enzymatic processes, but once 
activated, bioenergetic demand may be the most critical limitation of 
sporozoite viability. 
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On the basis of the results present here, it is concluded that AAT 
antagonizes C. parvum excystation by gaining direct assess to sequestered 
sporozoites; some degree of enhanced oocyst wall permeability is necessary for 
AAT to inhibit excystation. Further, it is apparent that sporozoite activation 
within the intact oocyst wall includes, at least in part, the expression of 
proteolytic enzyme activity. It is the association of proteolytic enzyme activity 
with excystation, and the functional specificity of the AAT molecule for the 
active site of serine proteases, that provides the most likely mechanism for 
serpin-mediated inhibition. The alteration in excystation dynamics caused by 
AA T accounts for its anticryptosporidial activity against in vitro infection, 
putatively by altering endogenous proteolytic activity within the otherwise 
intact oocyst. 
In an attempt to compensate for the waning efficacy of AAT with 
continued post-inoculation intervals, a multiple compound treatment 
strategy was evaluated. A study was designed to exploit the 
anticryptosporidial efficacy of 2 compounds that theoretically targeted 
different stages in the parasite's life cycle. AAT, an apparent excystation 
antagonist, and paromomycin, reportedly effective against asexual 
intermediates (i.e., type I and II meronts), were applied both individually and 
in combination in an in vitro test system. The combined serpin-
aminoglycoside activities exhibited a potent anticryptosporidial effect in the 
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BFTE cell culture system. Further, using the criteria of FIC indices, the study 
demonstrated that a significant synergistic response was achieved. 
The therapeutic application of protease inhibitors in the treatment and 
prevention of human cryptosporidiosis is premature; considerable research is 
necessary to better understand the systemic effects of exogenous inhibitors. 
The results presented in this dissertation demonstrate a potent antiparasitic 
effect for select protease inhibitors in the absence of observed cytotoxicity. The 
exact nature of excystation antagonism remains to be fully described; 
however, it is likely related to serpin activity on one or more cryptosporidial 
serine proteases requisite to proteolytically enhanced modification of the 
oocyst wall that facilitates full emergence of the infective sporozoite. 
Isolation and characterization of the protease(s) associated with excystation 
will provide a definitive answer to the hypothetical significance of enzyme 
activity in excystation and invasion of epithelial cells. 
While proteases certainly provide opportune targets for antimicrobial 
intervention, full therapeutic utility of protease inhibitors in the treatment of 
cryptosporidiosis will likely require the development of synthetic inhibitors 
with a substantial degree of parasite specificity. This approach is best 
illustrated by the recent inclusion of synthetic protease inhibitors in antiviral 
protocols for the treatment of HIV infection in humans. Clinical application 
of protease inhibitors and substrates as anticryptosporidial agents is 
dependent upon demonstrating the relevance of targeted proteases to 
infection and the vulnerability of these targets to chemotherapeutic agents. It 
is, therefore, essential that cryptosporidial proteases be isolated and 
characterized to include a thorough description of their function in the 
parasite's life-cycle. 
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The collective contribution of these assembled manuscripts is a solid 
foundation for future efforts to characterize the structural detail of 
cryptosporidial proteases related to excystation and early infection dynamics. 
Protein sequence data and homology comparisons to previously described 
proteases, both protozoan and mammalian, will provide researchers with a 
defined target and enhance the potential for effective clinical intervention. 
Inhibition of protease activity is a scientifically and clinically proven method 
for preventing infection and ameliorating the pathology associated with 
infectious disease processes. The further application of this strategy directed 
against parasitic infection is a logical extension of existing scientific and 
medical achievement and potentiates the development of a potent arsenal of 
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